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CHAPTER I 
AN INTRODUCTION WITH A REVIEW OF THE LITERATURE 
Bovine Brucellosis 
Introduction 
Brucellosis is an acute and chronic infectious disease of 
domestic animals transmissible to man causing undulant fever 
(McCullough, 1970). Bovine brucellosis caused by Brucella abortus is 
characterized principally by abortion or delivery of a non-viable 
calf, reduction in fertility, and decreased milk production. Except 
countries where it has been eradicated, bovine brucellosis is 
prevalent on every continent and is of economic importance because it 
results in reduced beef production due to the loss of calf crop from 
abortion, non-viable calves and decreased fertility (Alton et al., 
1975; Matyas and Fujikura, 1984). 
The magnitude of the global economic losses can be envisaged 
because the annual losses in Latin America alone has been estimated to 
be $700 million (Adbussalam and Fein, 1976). The seriousness of 
brucellosis in terms of human illness and economic loss has been a 
matter of major concern to national, public, and international 
organizations, particularly the World Health Organization and Food and 




Etiology and Pathogenesis 
Brucella abortus, the major etiological agent of bovine 
brucellosis, is a small, gram-negative, short rod or coccobacillus 
( 0 • 5 - 0 • 7 urn by 0 • 6 - 1 • 5 urn) . The organism is usually arranged 
singly and does not possess a capsule, flagellae, or endospores 
(Gillepsie and Timoney, 1981). Brucella abortus is divided into nine 
biotypes. The criteria used for biotyping are C02 requirement for 
growth, production of hydrogen sulfide, growth on dye media (basic 
fuchsin and thionin), and agglutination in monospecific antisera (A&M 
antigens) (Morgan, 1984). Although there does not appear to be 
differences in virulence among the biotypes, 85% of all documented 
infections are due to biotype 1 (Nicoletti, 1980). 
Brucella abortus is primarily a facultative intracellular 
bacterium because it is capable of surviving and multiplying within 
host macrophages (Braude, 1951). The bacteria have a predilection for 
the reticuloendothelial system, particularly mononuclear phagocytes. 
However, intracellular growth occurs in other cell types such as 
fibroblasts, endothelial cells, and chorionic trophoblasts. Theobald 
Smith (1919) was the first to report the intracellular habitat of ~ 
abortus by observing the localization of the bacterium within 
epithelial cells of the bovine fetal membrane. 
The most important means for transmission of the disease is by 
direct contact of a susceptible animal with an infected animal, its 
tissues or secretions and excretions. Mucous membranes are the usual 
portal of entry. These include mucous membranes of the oropharynx, 
upper respiratory tract, and conjunctivae (McCullough, 1970). Most 
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cattle acquire natural infection by ingesting infected or contaminated 
material. Experimentally, the conjunctivae is used most commonly as a 
route of inoculation. 
Besides the reticuloendothelial system, ~ abortus has a marked 
predilection for the gravid uterus (Pearce et al., 1962), which it 
reaches hematogenously. Following initial invasion of the host, the 
organism localizes in the regional lymph nodes and subsequently 
spreads to other lymphoid tissues including the spleen. Corner et al. 
(1987), investigated the distribution of~ abortus in naturally and 
experimentally (conjunctival challenge) infected cattle by isolation 
through bacterial culture. They showed that, in pregnant cows, the 
mammary lymph node was the most frequently infected tissue, whereas in 
nonpregnant heifers, ~ abortus was isolated most frequently from the 
mandibular lymph node. Due to the intracellular nature of the 
bacterium, bacteremia is rarely detected during the incubation period 
or in an animal with latent infection. However, following pregnancy, 
there is massive proliferation of the organism in the uterus. Several 
factors may account for this. Pearce et al. (1962), demonstrated that 
erythritol, a carbohydrate substance present in the placenta and fetal 
fluids, is a strong growth stimulant of ~ abortus. ~ abortus 
preferentially utilizes erythritol over glucose; therefore, the 
presence of erythritol in these tissues may account for the massive 
proliferation of ~ abortus in the gravid uterus (Pearce et al., 
1962). Also, ruminant placentae produce progesterone (Heap et al., 
1983), which has been shown to suppress cell-mediated immunity during 
pregnancy ( Szekeres et al., 1981). These factors could depress the 
host's immune system reducing the host's ability to control the 
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replication of ~ abortus. 
Following invasion of the pregnant uterus, ~ abortus first 
localizes in the uterine wall and then spreads to the uterine lumen 
(intercotyledonary spaces) leading to a severe ulcerative endometritis 
with subsequent destruction of the villi (Payne, 1959). Trophoblasts 
are believed to be the primary cell type involved in the entry, 
localization, and replication of ~ abortus in placentae (Anderson et 
al., 1986). Abortion occurs typically in the last three months of 
gestation with the incubation period dependent on the stage of 
gestation, dose of bacteria, and age and immunological status of the 
host (Nicoletti, 1980). The important fetal lesions in brucellosis 
are multifocal bronchitis and bronchopneumonia with a predominant 
mononuclear cell infiltration (Jubbs and Kennedy, 1985). 
Vaccines 
Strain 19 vaccine. The most economically feasible and effective 
way to control bovine brucellosis is through an effective vaccination 
and epidemiological survey/elimination program. ~ abortus strain 19 
(Sl9) vaccine is presently the most effective vaccine for the control 
of bovine brucellosis. This vaccine is used in the United States and 
in many countries where the disease is prevalent. Sl9 was originally 
isolated in 1923. Buck (1930) reported Sl9 to be of reduced virulence 
compared to field isolates, and it was efficacious when used as a 
vaccine for cattle (Alton et al., 1975). Sl9 vaccine was officially 
approved for use in the United states brucellosis program in 1939 
(Nelson, 1977). Vaccination of heifers with Sl9 effectively increases 
the resistance to brucellosis and thereby helps control the disease. 
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However, despite the beneficial effects of S19, residual poet-vaccinal 
titers, aberrant serologic reactions, and chronic infections with S19 
may occur and interfere with diagnostic serologic tests (Corner and 
Alton, 1981; Sutherland et al., 1982). Furthermore, S19 is a live 
vaccine, capable of infecting humans and constitutes a public health 
hazard. 
Other ~ abortus vaccines. Another vaccine that is used for 
immunizing cattle against brucellosis is the killed ~ abortus strain 
45/20 (S45/20) vaccine. S45/20 is a rough strain of ~ abortus and 
lacks the outer a-polysaccharide of the LPS (Moreno et al., 1984). 
Therefore, S45/20 vaccine induces low levels of agglutinating antibody 
and does not interfere with diagnostic agglutination tests. 
Furthermore, being a killed vaccine it is not infectious to humans. 
This vaccine was first described by McEven and Samuel (Cunningham, 
1977) and is used predominantly in Ireland and Austalia. The official 
vaccine K45/20A contains a standard adjuvant. Two vaccinations are 
necessary to induce immunity, and it is ineffective when given before 
six months of age (Cunningham, 1977). The advantages and 
disadvantages of S19 and K45/20A vaccines have been compared and 
reviewed (Cunningham, 1977). 
Several other vaccines have been examined as potential immunizing 
agents against brucellosis. These vaccines include the mucoid (M) 
vaccine of Huddleson (1947), the ~ melitensis strain H38 of Renoux 
(Renoux et al., 1964), and several extractable soluble substances from 
~abortus (Gillepsie and Timoney, 1981; Confer et al., 1987). 
vaccines have not gained acceptance. 
These 
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Role of Antibody in Resistance 
The host responds to Brucella sp. infection by producing a 
variety of serum antibodies representing most classes of immunoglobins 
(Sutherland, 1980). However, serum antibody responses do not 
correlate with immunity since heifers vaccinated with 519 may be 
immune to challenge despite low antibody titers within a few months 
after vaccination (McDiarmid, 1957; Cunningham and O'Reilly, 1968). 
In fact, high serum antibody titers correlate with chronic infection 
rather than resistance (Kreutzer et al., 1979). However, in the 
murine model of brucellosis, humoral immune responses may contribute 
to protection (Sultzeanu, 1965; Plommet and Plommet, 1983; Winter et 
al., 1988). 
Role of Cell-Mediated Immunity (CMil 
in Resistance 
!L... abortus is a facultative, intracellular bacterium and 
development of immunity requires activation of host cell-mediated 
immune responses (Sutherland, 1980; Plommet et al., 1985; Person et 
al. , 1987). Acquired resistance to brucellosis requires antigen-
specific T-cells (Jones and Buening, 1983) and activated macrophages 
(Cheers and Pagram, 1979). Macrophages from immunized cattle have 
increased capacity to kill the organism (Holland and Picket, 1958). 
Fitzgeorge et al. (1967), demonstrated that~ abortus multiplied more 
slowly in the macrophages of vaccinated cattle than in control 
animals. Adoptive transfer of resistance in mice using immune T-cells 
was reported (Pavlov et al., 1982; Madraso and Cheers, 1984; Plommet 
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et al., 1985) • 
The lymphocyte blast transformation (LBT), the macrophage 
migration inhibition test (MMIT), leukocyte migration inhibition test 
(LMIT), and delayed type hypersensitivity (DTH) test are generally 
used to assess CMI function following exposure to antigen (Sutherland, 
1980). The LBT is a test for the general assessment of T-cell 
function and measures the cell division of lymphocytes following 
stimulation by antigen or mitogen. In bovine brucellosis the LBT has 
been used to evaluate the CMI responses to antigens in infected and 
immunized animals (Kaneene et al., 1978; Klesius et al., 1978; Baldwin 
et al., 1984). The use of the LBT assay was proposed as a diagnostic 
test for bovine brucellosis (Kaneene et al., 1978); however, it has 
not been used widely. 
Potential Mechanisms of Brucella Immunity 
The Role of the Macrophage in Host Defense 
The first defense of the immune system after pathogenic invasion 
involves the phagocytes and antigen nonspecific cytotoxic cells. 
Macrophages, in particular, function as the first line of defense 
against invading microorganisms via nonspecific or opsonic 
phagocytosis. The mechanisms of activation of phagocytes and their 
role in immunity against different pathogens have been described 
(McCullough, 1970; Adam et al., 1984; Lukacs et al., 1985). 
~ abortus is primarily an intracellular parasite to which 
protective immunity may be dependent on antigen-specific effector T-
cells and macrophage bactericidal activity (Cheers, 1984). several 
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investigators described the mechanisms of anti-bacterial CMI 
(Mackaness, 1971; North, 1974; Collins, 1978; Kaufmann, 1987; Mielke 
et al., 1988). 
Neutrophils are capable of phagocytizing Brucella sp. organisms, 
but they have limited bactericidal capacity. Virulent ~ abortus 
inhibits the myeloperoxidase halide antibacterial reaction of 
neutrophils due to specific suppression of degranulation of 
peroxidase-positive granules (Caning et al., 1985; Bertran et al., 
1986). However, opsonization of ~ abortus with specific antibody 
stimulates an oxidative metabolic burst (Canning et al., 1988). 
Using the murine system model, it was demonstrated that the 
macrophage is the most important host cell for killing Brucella 
organisms (McCullough, 1970). Mononuclear phagocytes, tissue 
macrophages, and fixed phagocytic cells of the reticuloendothelial 
system are all responsible for the elimination of Brucella sp. in both 
the normal and the immune animal (McCullough, 1970). Following 
introduction of .!L._ abortus into host tissues (by intravenous, 
subcutaneous, per as, intradermal, intranasal, intraconjunctival, or 
aerogenic routes), the organism encounters different populations of 
resident phagocytic cells. The bacteria can then reach the blood 
stream via infected macrophages within lymphatics and colonize the 
liver and spleen (Collins et al., 1977). Although a small amount of 
the inoculum reaches the liver and spleen, this splenic inoculum 
appears to determine the degree of systemic immunity expressed by the 
immunized host (Collins et al., 1977; Collins and Campbell, 1982). In 
the absence of splenic involvement, there is a minimal systemic 
resistance mounted against the bacteria (Collins and Carter, 1974). 
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Resident macrophages play an important role during the induction 
of the immune response. By means of phagocytosis, they limit the 
growth of Brucella sp. organisms in the extracellular environment, 
serve as antigen presenting cells (APC) for helper T-cells, and 
prevent cellular damage by detoxifying enzymes and metabolic products 
released into the tissues by the rapidly multiplying bacteria (Collins 
and Campbell, 1982). However, unless activated, macrophages have 
little bactericidal capacity for Brucella .§.12.· In the murine 
listeriosis model, Mackaness (1969) demonstrated that macrophage 
activation and granuloma formation depend on specific lymphocytes, 
especially T-cells. T-cells activate macrophages via the production of 
soluble products ( lymphokines), in particular macrophage activating 
factor (MAF), now designated interferon-gamma (IFN-g) (Nathan et al., 
1983). Lymphokines are active in both macrophage recruitment and 
macrophage activation. MAF increases Fe receptors and promote 
phagocytosis via the C3b receptor. The immunologically-activated 
macrophage is larger, more mobile, and metabolically more active with 
increased bactericidal activity (Mackaness, 1970). Macrophage 
activation is nonspecific, and activated macrophages can kill tumor 
cells and intracellular parasites more effectively. Macrophage killing 
of intracellular microbes requires the generation of oxygen 
intermediates, i.e., hydroxyl radical and singlet oxygen or hydrogen 
peroxide. Thus, with regards to infection with Brucella sp., the most 
important attribute of the activated macrophage is enhanced 
bactericidal capacity. In fact, macrophages from immunized cattle have 
increased capacity to kill Brucella sp. (Holland and Pickett, 1958; 
Fitzgeorge et al., 1967). Therefore, macrophages are the effector 
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cells, and T-cells are mediators in the induction of CMI in 
brucellosis (Cheers, 1984). 
The Role of the T-cell in the Induction of 
Acquired Resistance 
Infections by facultative intracellular bacteria, such as 
Brucella sp., are characterized by the formation of granulomas 
macrophage activation, and the development of DTH (Mackaness, 1962, 
1971) • It was recently shown that T-cells are mediators for the 
induction of acquired resistance (CMI) to brucellosis (Cheers, 1984; 
Plommet, 1985). However, expression of the CMI response requires 
interaction between macrophages and immunocompetent T-cells 
(Mackaness, 1971; North, 1974; Splitter and Everlith, 1986). 
In contrast to antibodies which bind free antigen directly, T-
cells recognize foreign antigen in association with products encoded 
by the major histocompatibility complex (MHC) on the surface of host 
cells. Macrophages phagocytize foreign antigen, process it 
biochemically, and present the processed antigen to helper T-cells in 
association with MHC class II molecules (Unanue and Allen, 1987). 
During this process, APC produce a lymphocyte activating factor, 
interleukin-1 (IL-l). 
IL-l activates the T-cell and induces the expression of receptors 
for the T-cell derived lymphokine interleukin-2 (T-cell growth factor) 
(Dinarello, 1984). Activated T-cells are capable of proliferating in 
response to IL-2. Antigen and IL-2 also cause pre-cytotoxic T-cells to 
proliferate and differentiate into effector cells. The expansion of 
antigen- specific (i.e., Brucella sp. specific) T-cells is induced and 
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sustained by IL-2. Activated T-cells release a number of lymphokines 
such as macrophage chemotactic factor (MCF), macrophage-migration-
inhibition factor (MIF), and IFN-g, which induce macrophage 
accumulation and activation. Thus, the most important function of 
Brucella-sensitized helper T-cells is the attraction, focusing, and 
activation of macrophages at the infected site (i.e., to the site of a 
DTH response to an injection of Brucella antigen). Also, IFN-g induces 
expression of Ia (immune response associated) molecules on the 
macrophage (Steeg et al., 1982). 
Immunocompetent T-cells have the ability to recognize foreign 
antigen entering the tissues. Sensitized T-cells are extremely mobile 
(Koster et al., 1971) and migrate to infective foci, thereby 
increasing their chances of association and recognition of sensitizing 
antigens. As T-cells migrate in increasing numbers into the 
inflammatory focus, they come into contact with processed antigen 
presented by the infected macrophages (Collins, 1979) . These cells 
will then undergo blast transformation which causes a concomitant 
clonal expansion of immunocompetent T-cells with subsequent 
manifestation of the immune response. Stimulated T-cells release a 
number of previously described lymphokines into the tissues which, in 
turn, activate surrounding macrophages and can result in the eventual 
resolution of the infection (Mackaness, 197la,b). 
Acquired resistance to most facultative intracellular parasites 
is relatively short-lived. The immune response is mediated by a 
population of short-lived small lymphocytes, which following 
infection, increase sharply in numbers then rapidly decline (North, 
1973). A decline in memory cells has been observed in response to 
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Brucella sp.- and Salmonella sp.-infected mice (Collins, 1971). 
Despite the rapid reduction in the numbers of detectable sensitized T-
cells, the convalescent host can upon challenge mount an accelerated 
recall of the earlier immune response (North, 1975). This anamnestic 
response is mediated by a population of long-lived memory T-cells 
thought to persist within the spleen and lymph nodes, even in the 
absence of the sensitizing antigen (Collins and Campbell, 1982). When 
exposed to the triggering antigen or active infection, such memory 
cells will undergo rapid clonal expansion resulting in large numbers 
of specifically sensitized T-cells capable of mediating an anamnestic 
response (Cohen and Livnat, 1976). 
Recently, Kaufmann ( 1988) showed that cytotoxic T-cells could 
lyse Listeria-infected !a-positive bone marrow macrophages in vitro. 
This contradicts the widely accepted idea that activated macrophages 
are the main defense against facultative intracellular bacteria. 
However, it has been demonstrated that both helper and cytotoxic T-
cell subsets are important in protection against Listeria 
monocytogenes, a facultative intracellular bacterium (Bishop et al., 
1987; Czupryinski et al., 1987). This mechanism has been demonstrated 
for other intracellular microbes (Orme, 1987; Pedrazzini, 1987). 
Recently, cytotoxic T-cells were shown to potentially protect mice 
from malaria infection (Schofield et al., 1987; Mogil et al., 1987). 
Lysis of Brucella sp.- infected cells by cytotoxic T-cells has not 
been demonstrated. Kaufmann (1987) proposed that since virtually all 
nucleated host cells express MHC class I molecules, association of 
bacterial antigens with class I molecules permits identification of 
infected cells independent of their type and origin. Thus, class I-
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restricted cytotoxic T-cells, with specificity for bacterial antigens, 
could identify and lyse most infected host cells. 
Suppressor T-cells, Immunosuppression 
and Tolerance 
The immune response of an individual following introduction of 
antigens via vaccination consists of a rapid recruitment of 
immunocompetent cells with release of soluble factors. The hallmarks 
of this response are specificity, an enormous repertoire for 
recognition, and an ability to recall previous immunogenic challenges 
(Bankert et al., 1981). However, as with any physiological system, it 
must be regulated to be efficient. Immunologic reactions are 
regulated and represent the net balance of stimulatory and suppressor 
functions. During an immune response, suppressor cells and anti-
idiotypic antibodies are considered to have regulatory functions in 
the immune response. Depending upon the relative balance between 
inhibiting factors and reactive lymphocytes, a lymphoproliferative 
response may or may not be detected. Stimulation of helper T-cells 
ultimately results in induction of suppressor T-cells circuits (Flood 
et al., 1986). This is important to avoid overproduction of helper T-
cells and their factors. When IFN-g, IL-l, or IL-2 reach a minimum 
level a suppressive activity is induced through the suppressor T-cell 
circuit (Hausman et al., 1986). 
Gershon (1970) was the first to describe suppressor T-cells while 
investigating immune tolerance in mice. In a synthetic peptide 
terpolymer system, Pierce et al (1979) have described two suppressor 
factors, one specific and the other nonspecific. 
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Suppressor T-cells are important in the regulation of the immune 
response and in tolerance, as they are able to suppress either helper 
or effector T-cells (Miller, 1975). Following activation by antigen on 
APC, suppressor inducer T-cells produce an antigen-specific factor 
TsF1 (T-lymphocyte suppressor factor one). This factor activates the 
suppressor T-cell precursor, which may bind TsF1 through specific 
recognition of the TsF1 idiotype. The precursor differentiates into or 
activates pre-existing effector suppressor T-cells. These suppressor 
cells may down regulate the immune response by two postulated 
mechanisms: 1) suppressor cells may bind helper T-cells through 
recognition of the idiotype of the helper T-cell antigen receptor, 
blocking the binding of antigen to the helper T-cell; 2) suppressor T-
cells may release soluble suppressor factors that bind antigen bound 
helper T-cells, leading to shutdown of helper T-cell activity 
(Johnston, 1985). 
A variety of products of microbial origin have been shown to 
modulate the immune system (Schwab, 1977), and some bacterial agents 
can suppress various phases of specific immunity (Schwab, 1975, 1983). 
Mostly facultative or obligate intracellular bacteria are implicated 
in immunosuppression. These organisms can survive and multiple in 
macrophages. Several examples of natural and experimental chronic 
infections have been described in which progressive uncontrolled 
infection is associated with a depressed CMI. These include 
tuberculosis, leprosy, pseudomoniasis, and trypanosomiasis (Watson et 
al., 1981; Schwab, 1983; Liew et al., 1987; Nakamura et al., 1989). 
A decreased lymphoproliferative response to phytohemaglutinin 
(PHA) was described in humans with acute and chronic brucellosis 
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(Renoux and Renoux, 1977). In experimental murine brucellosis, 
inhibition of lymphoblastogenesis to several mitogens was attributed 
to splenic macrophages (Riglars and Cheers, 1980). Macrophages 
infected with Brucella sp. inhibit or suppress in vitro proliferation 
of T-cells (Splitter and Everlith, 1989). Macrophage-mediated 
immunosuppression was reported in several diseases (Allison, 1978; 
Elmer, 1978; Snyder et al., 1982). The susceptibility of mice to 
chronic infection with !L_ abortus is believed to be mediated by a 
suppressor mechanism (He and Cheers, 1982). 
Macrophages have a dual role in the regulation of the immune 
response because they supply both activating factors for lymphocytes 
as well as inhibitory factors (Chouaib and Fradelizi, 1982). Many 
studies have shown that arachidonic acid metabolites synthesized by 
macrophages have important immunoregulatory functions (Goodwin et al., 
1980; Stenson et al., 1980; Petit et al., 1985). Activated macrophages 
could inhibit T-cell-macrophage interaction during antigen 
presentation by regulating Ia expression through prostaglandin 
synthesis (Petit et al., 1985). IL-l produced by activated macrophages 
can induce the production of adrenocorticotrophic hormone, which 
increases plasma cortisol levels. High plasma cortisol levels have 
been shown to be associated with depressed immune responses in calves 
(Roth and Kaeberle, 1983; Blecha and Baker, 1986). 
Suppression of CMI to ~ monocytogenes, may be mediated by 
prostaglandins secreted by activated macrophages (Petit et al., 1985). 
Thus, the mechanism responsible for the control of facultative 
intracellular bacteria may result in the inhibition of specific T-cell 
functions. 
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Immune stimulation with high doses of antigen often induces 
tolerance. Under these conditions the regulatory system enhances the 
suppressor T-cell. A more normal immunogenic dose enhances helper and 
contrasuppressor T-cells (Johnston, 1985). 
The Role of Cellular Mediators 
Soluble factors produced by immunocompetent cells in response to 
antigenic stimulation represent one communication link by which the 
immune system regulates its activities (Webb et al., 1983). Soluble 
mediators secreted by one cell bind to and modify the biological 
activity of another cell (Johnston, 1985). 
Soluble factors that serve in the regulation of cellular 
hypersensitivity and immunity were discovered with the demonstration 
of MIF associated with DTH (Bloom and Bennet, 1966). Soluble mediators 
secreted by lymphocytes or monocytes are called lymphokines or 
monokines, respectively. Lymphokines are released by activated T-cells 
when they react with the antigen to which they were specifically 
sensitized. 
IL-l, a protein secreted by stimulated macrophages, induces the 
production of IL-2 by helper T cells and is, therefore, necessary for 
lymphocyte proliferation. Besides inducing proliferation, IL-l stimu-
lates the liver to secrete acute-phase proteins, which are important 
in acute inflammatory responses. Bovine IL-l can be measured using a 
murine IL-l dependent cell line (DlO.G4: 1) (Everlith and Splitter, 
1989). 
Tumor necrosis factor ( cachectin) (TNF-a), a monokine secreted 
mainly by macrophages, exerts profound and important biological 
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effects on a variety of cells in the host (Nathan, 1987). TNF has also 
been shown to act synergistically with IFN-g to enhance the macrophage 
activation (Esparza et al., 1987). In fact, TNF is important in host 
defense against~ monocytogenes infection (Nakane et al., 1988). 
T-cells secrete a variety of lymphokines which are important in 
regulating the activity of the entire immune system. CMI is mediated 
through the collective action of lymphokines and cytotoxic T-cells. 
IL-2 is a glycoprotein secreted by T-lymphocytes after antigen and IL-
l stimulation. It is required for proliferation and clonal expansion 
of antigen- or mitogen- activated T-cells by acting on IL-2 receptors 
that are induced on activated T-cells. It also induces the synthesis 
of other lymphokines (Bendtzen, 1985; Alm, 1987). Besides IL-2, 
activated T-cells secrete a variety of other soluble factors including 
IFN-g, MIF, MCF, and GM-CSF. IFN-g induces expression of Ia molecules 
on macrophages and other APC, is a potent activator of macrophages, 
enhances the production of IL-l, and enhances intracellular killing of 
bacteria by macrophages. MCF recruits macrophages to the site of 
infection, whereas MIF keeps the attracted cells localized the at the 
focal site of antigen release. In addition, T-cells secrete 
suppressor factors that inhibit helper T-cell activity and down 
regulate the immune response. 
In summary, potential mechanisms of immunity to Brucella sp. 
could be postulated as follows: Brucella organisms are phagocytized by 
macrophages and proliferate within cells. Macrophages degrade the 
bacteria, process antigens for presentation, and subsequently activate 
specific T-cells. Recognition of Brucella sp. antigens leads to the 
induction of CMI and DTH. Sensitized T-cells proliferate or secrete 
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lymphokines which have three effects: enhanced macrophage 
bactericidal activity, recruitment of monocytes from the hemopoietic 
tissue to the site of infection, and local proliferation of 
macrophages. Activated macrophages form granulomas and eliminate 
intracellular bacteria. Suppressor T-cells may block these pathways by 
inhibiting either the interaction between T-cells and APC or by the 
release of lymphokines. The immune response is further mediated by 
lymphokines and monokines. 
The identification of the cell type responsible for most 
effective protection against brucellosis and the characterization of 
the cellular events that leads to its induction are crucial in the 
development of efficacious vaccines against Brucella sp •. 
Adjuvants for Enhancing Immune Mechanisms 
An adjuvant may be defined as any agent that acts nonspecifically 
to augment an immune response to a specific antigen (Allison, 1979). 
Vaccination has long been considered as the most effective way of 
protecting an organism against pathogenic microorganisms. The success 
of a vaccination program depends both on the immunogenicity of the 
vaccine and the capacity of the host to mount an adequate immune 
response to the vaccine (Bizzini, 1984). 
One main application of adjuvants is the potentiation of vaccines 
either by increasing the immunogenic potency of the vaccine and/or 
enhancing immunological responsiveness to a vaccine. By augmenting the 
efficacy of vaccination, an appropriate adjuvant could induce long-
lasting immunity using a low dose of antigen and thus minimizing side 
effects of vaccination. An adjuvant can enhance humoral or cell-
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mediated immunity or both. Thus, the choice of an adjuvant for any 
vaccine should be determined by the relative role of humoral and CMI 
in protecting the host against the infectious agent. 
A myriad of immunopotentiating agents have been described in the 
literature, but only a few have . been used in human and veterinary 
vaccination programs. This review of adjuvants is not intended to be 
comprehensive. It is a brief disc.ussion of adjuvants used for humoral 
and cellular immunity, especially those capable of enhancing cellular 
response for Brucella sp. vaccines. The nature, chemistry, and action 
of immunological adjuvants of human and veterinary importance have 
been the subject of numerous reviews in the last 10 years (Aubry et 
al., 1979; Allison, 1979; Osebold, 1982; Cancelotti and Galassi, 1984; 
Adam, 1985; Lefrancier, 1985; Warren et al., 1986; Nervig et al., 
1986; Dalsgaard, 1987). 
Adjuvants for Humoral Immunity 
Aluminum salts are widely used adjuvants for immunogens that 
require antibody responses to induce protection. Aluminum forms a 
precipitate with the antigen (alum-antigen precipitate) • The alum-
antigen precipitate localizes the antigen at the site of subcutaneous 
or intramuscular injection. The delayed absorption of the antigen 
makes it available to the immune system for a prolonged period, with 
enhancement of the immune response resulting from exaggerated, long 
term secondary stimulations (Kaeberle, 1986). The adjuvant effect of 
aluminum enhances antigen-specific IgG responses and is thought to be 
due to the delayed rate of absorption of the precipitated antigen 
(Bunn et al., 1986). It was also reported that aluminum can activate 
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complement (Ramanathan et al., 1979), which may in turn activate 
macrophages and increase their phagocytic activity. Because of their 
safety, aluminum salts have been used in human and veterinary 
biologics. In veterinary biologics, aluminum hydroxide gel is the 
most commonly used adjuvant. 
Saponin is another adjuvant that has been used in a variety of 
veterinary vaccines, in particular foot and mouth disease virus 
(Dalsgaard, 1978). Saponin is a glycoside of plant origin and it is a 
surface-active adjuvant due to its amphipathic nature. It augments 
humoral responses and does not appear to stimulate CMI responses 
(Bamford, 1980). Saponin interacts with cell membranes and activates 
phospholipase A, with resultant formation of surface-active 
lysophosphatidylcholine, which inhibits prostaglandin synthesis. 
Inhibition of prostaglandin synthesis reduces the negative effect of 
prostaglandin on lymphoid cells, with a resultant augmentation of 
immune responses (Kaeberle, 1986). 
The oil adjuvants (water-in-oil) consist of a highly purified 
mineral oil combined with an emulsifying agent such as Arlacel-A. The 
oil adjuvants retain a portion of the antigen at the site of 
injection, leading to a gradual and continuous release for stimulating 
antibody production. They alter lymphocyte recirculation by 
localizing lymphocytes in draining lymph nodes and they enhance the 
accumulation of lymphocytes and macrophages in lymph nodes draining 
sites of inflammation, infection or antigenic challenge. This 
facilitates interaction between cells that participate in immune 
responses (McKercher, 1986). Oil adjuvants increase the immune 
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response to most antigens and generally prolong the duration of 
immunity. They have been used to increase antibody responses for 
vaccines against such diseases as rabies, canine distemper, infectious 
canine hepatitis, hog cholera and foot and mouth disease (McKercher, 
1986). However, the greatest use of oil adjuvants appear to have been 
with foot and mouth disease vaccines, particularly in those for use in 
swine. 
Nonionic block copolymers, and Freund's incomplete adjuvant 
(FIA) potentiate humoral immune responses (Hunter and Bennett, 1986; 
Opdebeeck and Norcross, 1984) . The nonionic block copolymers are 
surface-active agents consisting of a central polymer of 
polyoxypropylene (POP) which is hydrophobic, flanked by polymers of 
polyoxyethylene (POE) which is hydrophilic. The copolymers are 
adhesive molecules which can promote adhesion of proteins to one 
another or to cells. They promote adhesion of antigens to APC leading 
to effective presentation of antigen to T-cells. They also activate 
complement by the alternate pathway and C3b on the surface may 
facilitate localization of antigens on the surface of APC (Hunter and 
Bennett, 1986). FIA is an oil adjuvant without killed tubercle 
bacilli. The mode of action of FIA is similar to that of the oil 
adjuvant described above. FIA causes production of soft local 
granulomas that are rich in macrophages, lymphocytes, and plasma 
cells. FIA induces secondary antigen depots in lymph nodes, spleen, 
and lungs. Localization of antigen at injection site provides a 
persistent stimulus for antibody production (Osebold, 1982). 
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Adjuvants for Cell-Mediated Immunity 
Freund's complete adjuvant (FCA), an emulsion of mineral oil and 
killed Mycobacteria sp., is one of the most potent adjuvants known for 
stimulating both humoral and CMI. Sulfatides from Mycobacteria sp. 
inhibit phagosome-lysosome fusion in macrophages (Goren et al., 1976). 
The resultant incomplete digestion of the phagocytosed bacteria 
apparently contributes to the induction of a CMI response (Kaeberle, 
1986). CMI responses to both tuberculoproteins and test antigens are 
induced by FCA. FCA has limited clinical applications in domestic 
animals because it produces granulomas at the site of injection, 
fever, and toxic effects as well as tuberculin hypersensitivity. 
Bordetella pertussis (Tamura et al., 1985), Propionibacterium acnes 
(formerly called Corynebacterium parvum; Bamford, 1980), muramyl 
dipeptide (MOP, Audibert et al., 1985), dimethyl dioctadecyl ammonium 
bromide (DDA, Gordon et al., 1980), and trehalose dimycolate (TDM) 
(Lederer et al., 1987) . are adjuvants capable of potentiating CMI. 
Other adjuvants capable of stimulating CMI are levamisole (Brunner and 
Muscoplat, 1980), sodium diethyl dithiocarbamate (DTC) (imuthiol) 
(Adam, 1985), polyribonucleotides (Adam, 1985), and azimexon 
(Chirigos, 1984). 
The prin6ipal components of Bordetella pertussis are 
lipopolysaccharide (LPS) and pertussis toxin (PT). PT is a 
lymphocytosis-promoting factor that potentiates the CMI response by 
its ability to alter recirculation of T-lymphocytes by localizing 
lymphocytes in draining lymph nodes (Warren et al., 1986). PT also 
increases DTH responses. ~ pertussis stimulates macrophages to 
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release molecules that stimulates helper T-lymphocyte functions. The 
macrophage appears to be the mediator for many of the 
immunostimulatory activities induced by £.:._ ~ as well and it is 
believed that macrophage activation is primarily responsible for 
augmentation of CMI responses (Adlam and Scott, 1973; Filice et al., 
1980). ~ acnes-activated macrophages exhibit enhanced antigen 
processing (Wiener and Bandieri, 1975), phagocytic and bacteriostatic 
activity (Fauve and Herin, 1971). 
OOA, a synthetic lipophilic quartenary amine, and a cationic 
surface active lipid, enhances expression for Fe receptors, increased 
interleukin-1 production, and increased lysosomal enzyme activity in 
macrophages (Gordon et al., 1980; Kraaijeveld et al., 1982; Prager, 
1985). Inhibited phagosome-lysosome fusion in rnacrophages and 
enhanced OTH reactions result from use of OOA as an adjuvant (Snippe 
et al., 1982). 
MOP is the minimal structure capable of replacing Mycobacteria 
sp. in FCA and TOM is a glycolipid (cord factor) associated with cell 
wall of Mycobacteria sp. The macrophage is the main target cell for 
MOP and TOM. These compounds activate macrophage metabolism with a 
resultant increase in bactericidal and cytostatic activities and 
increased IL-l production ( Guenounou et al. , 1985; Garrec et al. , 
1986; Lederer et al., 1987). 
Levamisole and OTC are sulfur-containing compounds; however, OTC 
lacks the imidazole ring. They both enhance macrophage and T-
lymphocyte function and reduce suppressor T-cell function (Renoux and 
Renoux, 1979; Brunner and Muscoplat, 1980; Pompidou et al., 1985). 
The polyribonucleotides enhance helper T-cell activity through 
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increased synthesis of lymphokines and modulation of membrane 
receptors. Polyribonucleotides also activate macrophages and NK cell 
activity (Adam, 1985). Azimexon increases DTH responsiveness, 
stimulate T-lymphocyte functions and macrophage phagocytosis and 
natural killer cell activity (Chirigos, 1984). LPS, although long 
considered to be a potent polyclonal activator of B-cells can 
stimulate CMI responses as measured by DTH (Ohta et al., 1982). A 
number of these adjuvants (MDP, TDM, DDA, ~ acnes, and FCA) have been 
employed in experimental Brucella sp. vaccines in cattle and 
laboratory animals (Woodard et al., 1980; Woodard and Jasman, 1981; 
Winter et al., 1983; Montaras and Winter, 1986; Panangala et al., 
1986; Confer et al., 1987; Winter et al., 1988). 
Biological Response Modifiers 
Biologicals are products of the mammalian genome, and biological 
response modifiers (BRM) are agents when administered to an animal are 
capable of modifying the normal host defense mechanisms or immune 
responses. BRM are generally divided into two groups: 1) Those that 
are produced by the host and are a product of the host genome e.g. IL-
l, IL-2, and interferons; and those that are not products of the 
mammalian genome but which can potentially alter the individual's 
biologic response, e.g. MDP, TDM, and DDA. A brief discussion of the 
first group will be considered here. 
IL-l, a lymphocyte activating factor, is a protein secreted by 
activated macrophages. It stimulates the production of IL-2 by helper 
T-cells and is, therefore, necessary for lymphocyte proliferation. 
Thus, IL-l serves as an endogenous adjuvant, wherein it is a co-factor 
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during lymphocyte activation primarily inducing the synthesis of IL-2 
and the activation of the resting T-cell (Staruch and Wood, 1983). 
IL-2, a T-cell growth factor, is produced by activated T-
lymphocytes and is required for clonal expansion of activated T-cells. 
IL-2 also activates natural killer cells, enhances thymocyte 
proliferation, and induces cytotoxic T-cell activity. Bovine IL-2 has 
been produced in vitro, purified, characterized, and cloned (Cerretti 
et al., 1986; Magnuson et al., 1987). DNA recombinant techniques have 
produced purified products of IL-l and IL-2, making it feasible to 
investigate their role as adjuvants. The in vivo effects of 
exogenously administered IL-l and IL-2 on the immune system have been 
documented (Staruch and Wood, 1983; Rouse et al., 1985; Sharma et al., 
1985). 
Bovine IFN-a and IFN-g have been produced through recombinant DNA 
technology and evaluated in vivo in cattle and in vitro on bovine 
cells (Bielefeldt-Ohmann and Babuik, 1984; Steinbeck et al., 1986). 
Conclusion and Statement of the Thesis Problem 
Its beneficial effects not withstanding, the current Sl9 vaccine 
induces post-vaccinal antibody titers, aberrant serologic reactions, 
and chronic infections which may interfere with routine diagnostic 
serologic tests. The problems associated with Sl9 have spurred 
interest in the development of a !L_ abortus subunit vaccine which 
combines a few essential macromolecules of the Brucella surface. 
Numerous investigators have studied the immunogenicity of various 
subcellular fractions of Brucella (Montaraz and Winter, 1986; Confer 
et al., 1987; Winter and Rowe, 1988). However, subunit vaccines have 
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essentially low immunogenicity and have to be administered with an 
adjuvant to augment the immune response. 
The studies in this dissertation were conducted to evaluate, in 
cattle, the immunopotentiating effects of various adjuvants for use 
with non-living !L_ abortus antigens by comparing serum antibody and 
CMI responses induced by these experimental vaccines. Additionally, 
the CMI responses were assessed with regard to functional lymphocyte 
and mononuclear phagocyte activities from the peripheral blood of 
calves vaccinated with Sl9 or non-living vaccines. 
Three experiments were conducted. In experiments I and II, cattle 
were immunized with ~ abortus soluble antigen (BASA) plus various 
adjuvant preparations. In experiment III, the immunizing antigen was a 
soluble extract of gamma-irradiated ~ abortus (GBASA) which had 
reduced LPS content as compared to BASA. The CMI responses were 
evaluated using the lymphocyte-blast transformation assay and 
cutaneous DTH responses. The humoral immune responses were measured 
using standard serologic tests and immunoassays. 
These studies were conducted using the following working 
hypothesis: ( 1) protective immunity could be achieved in bovine 
brucellosis using a non-living vaccine with an appropriate adjuvant; 
and ( 2) the mechanistic basis of adjuvant actions in bovine 
brucellosis could be delineated by evaluating the CMI responses with 
regard to helper and suppressor cell activity and IL-l and IL-2 
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COMPARATIVE EFFECTS OF DIFFERENT ADJUVANTS ON THE 
IMMUNE RESPONSES IN CATTLE VACCINATED WITH 
BRUCELLA ABORTUS SOLUBLE ANTIGEN 
Introduction 
Bovine brucellosis, caused by Brucella abortus, is a complex 
disease associated with abortion and infertility in cows. Despite an 
eradication program with a live ~ abortus strain 19 (Sl9) vaccine, 
brucellosis remains a problem to the cattle industry in several 
regions of the country (Woodard, 1981). Vaccination of heifers with 
Sl9 induces resistance against brucellosis and thereby provides a 
measure of disease control. However, despite the beneficial effects 
of Sl9, interference with routine diagnostic serologic tests from 
residual post-vaccinal antibody titers, aberrant serologic reactions, 
and chronic infections with Sl9 may occur (Corner and Alton, 1981; 
Sutherland et al., 1982). Furthermore, Sl9, although attenuated for 
cattle is virulent for humans and thus, constitutes a human health 
hazard. Some of these problems associated with Sl9 have been 
decreased but not eliminated by using a reduced vaccinal dose (Barton 
et al., 1980). There is a need for an effective Brucella vaccine that 
would induce effective immunity without causing the problems currently 
associated with Sl9 (Alton, 1977). 
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It has been postulated that protective immunity can be induced 
for bovine brucellosis with a subunit vaccine with an appropriate 
adjuvant (Winter et al., 1983). An advantage of a subunit vaccine for 
brucellosis compared to a whole cell bacterin is the elimination of 
bacterial components that do not contribute to immune-mediated 
protection. Therefore, the presence of only one or two essential 
antigens in a subunit vaccine should eliminate the immune response 
against many irrelevant antigenic determinants of the organism 
(Bachrach, 1982). However, inactivated and purified soluble antigens 
often are weak immunogens and require a safe and effective adjuvant to 
effectively induce a strong immune response. 
Recently, Montaraz and Winter (1986) demonstrated protection of 
BALB/C mice against experimental ~ abortus infection at 1 week, but 
not at 4 weeks, following vaccination using ~ abortus cell envelopes, 
killed whole cells, or outer membrane proteins; therefore, the use of 
nonliving vaccines for control of bovine brucellosis may be feasible. 
However, Woodard and Jasman ( 1983) failed to protect cattle against 
brucellosis using a trehalose dimycolate-~ abortus strain 45/20 
bacterin. Confer et al ( 1987) failed to protect cattle from 
experimental brucellosis using a salt-extractable ~ abortus antigen 
in Freund's complete adjuvant. Most experiments regarding the immune-
potentiating capacities of various adjuvants in brucellosis have been 
studied in laboratory animals (Bosseray et al., 1984; Montaraz and 
Winter, 1986; Woodard et al., 1980), and these findings may not 
correlate well to such studies in cattle under field conditions. 
The purpose of these studies was to evaluate the immunopoten-
tiating effects of various adjuvants in conjunction with a nonliving 
42 
soluble ~ abortus immunogen preparation through comparison of serum 
antibody and cell-mediated immune responses. 
Materials and Methods 
Cattle. Sixty-four weanling crossbred beef steers, approximately 
250 to 300 kg each, were used. These steers were obtained from herds 
that had no clinical signs of brucellosis and were serologically 
negative for ~ abortus. They were transported to the Livestock Health 
Research Center in Hugo, Oklahoma, maintained on a bermuda grass 
pasture, and fed a protein supplement. 
Lymphoproliferation assay. Peripheral blood mononuclear cells 
(PBMC) were isolated from heparinized blood by Ficoll-hypaque density 
centrifugation as described (Confer et al., 1985). Two antigen 
preparations were used for the in vitro stimulations; heat-killed ~ 
abortus S1119 (HKA) prepared as previously described (Dorsey and 
Deyoe, 1982) or gamma-irradiated ~ abortus S19 (GBA, irradiated with 
1.4 Mrad from a 60co source, obtained from Dr. B.L. Deyoe, Ames, IA). 
The lymphoproliferation (LP) assays were conducted in triplicate in 
96-well microtiter plates (COSTAR, Cambridge, MA) as previously 
described (Confer et al., 1985). PBMC were used at a concentration of 
5 x 105 cells per well. Antigen-driven LP responses were determined to 
HKA (2 ug per well) (Experiment 1), and to HKA and GBA at 
concentrations of 1 ug, 2 ug, and 4 ug per well (Experiment 2). 
Pokeweed mitogen (PWM) was used as a positive stimulation control. The 
LP responses were determined by 3H-thymidine uptake (0.8 uCi per well, 
specific activity 30 mCi) over the final 18 hours of culture. A 
stimulation index ( SI) was calculated for each sample: SI = mean 
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counts per minute (CPM) for HKA-, GBA-, or PWM-stimulated 
cultures/mean CPM for unstimulated cultures. 
Serologic tests. The standard serologic tests used were the 
brucellosis card test (CARD), rivanol precipitation-plate 
agglutination test (RIV), and a microtiter complement fixation test 
(CF) (Alton et al., 1975). 
A quantitative fluorometric immunoassay [Fluorescent Immunoassay 
System (FIAX), (Whittaker M.A. Biologics) was performed according to 
the method of Hall et al ( 1984) using dialyzed f!...:.. abortus soluble 
antigen (BASA-d, Tabatabai and Deyoe, 1984). Sera were diluted 1/51 
(IDT Automatic Pipettor) in PBS containing 0.15% Tween 20. 
Fluorescein isothiocyanate-conjugated rabbit anti-bovine IgG (light 
and heavy chain specific) (Cappel Labs, Cockranvi1le, PA) was diluted 
to 1/800. A fluorometer was used to determine fluorescence for 
duplicate serum samples. The average ng of IgG binding was evaluated 
from a standard curve. 
The enzyme-linked immunosorbent assay (ELISA) was performed as 
previously described (Confer et al., 1985). Briefly, 100 ul of BASA-d 
in carbonate buffer (pH 9. 6) were used to coat the wells of 
polystyrene microtiter plates. Sera were used at a dilution of 1/250. 
Brucella-specific antibodies were identified with affinity purified 
rabbit antibovine IgG (light and heavy chain specific) conjugated with 
horseradish peroxidase (Pel Freeze, Rogers, AR). The color reaction 
was developed using a-phenylenediamine and H202. Mean OD490 was 
determined on duplicate samples and the ng of IgG per well determined 
from a standard curve. 
Delayed ~ hypersensitivity. As an in vivo correlate of cell-
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mediated immunity, delayed type hypersensitivity (DTH) to BASA was 
determined 35 days after vaccination (Experiment 2). Each steer was 
tested by intradermal injection of 50 ug of BASA antigen in a volume 
of 0.1 ml using tuberculin syringes with 25-gauge needles. A second 
skin site was injected with 0.1 ml of phosphate-buffered saline as a 
negative control. The double skin fold thickness was measured with 
calipers before injection of antigen or PBS and 30 hours later. An 
increase in double skin fold thickness of 2 mm or greater than the 
initial measurement prior to injection of antigen was considered as a 
positive reaction (Nicoletti, 1983). 
Adjuvants. The adjuvants used were of three general types: 1) an 
antigen depot adjuvant Freund's incomplete adjuvant (FIA); 2) 
bacterial adjuvants - Bordetella pertussis, Propionibacterium ~ 
(formerly designated Corynebacterium parvum), and the synthetic 
adjuvant-muramyl dipeptide (MDP), which is considered to be the 
minimal structure capable of replacing mycobacteria in complete 
Freund's adjuvant; and 3) a surface-acting adjuvant, 
dimethyldioctadecyl-ammonium bromide (DDA). The immunopotentiating 
activities of these adjuvants have been documented in cattle and other 
species (Bomford, 1980; Bomford, 1980; Snippe et al., 1982; Winter et 
al., 1983). 
Antigen. All steers receiving the soluble ~ abortus preparation 
were immunized with Brucella abortus soluble antigen (BASA) (obtained 
from the National Veterinary Services Laboratories, Ames, IA) (Berman 
et al., 1980). In both experiments, 2 mg of BASA (1 ml containing 2 mg 
protein) was mixed with either an equal volume of the relevant 
adjuvant or sterile saline plus the adjuvant to make a final volume of 
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2 ml. With each antigen-adjuvant preparation, a total volume of 2 ml 
was injected subcutaneously in the cervical region anterior to the 
scapula. 
Experiment 1· Thirty crossbred steers were equally allotted into 
6 groups. Group 1 (control) was not immunized. Group 2 was immunized 
with the standard reduced dose of S19. Group 3 was immunized with BASA 
only. Group 4 received a combination of BASA + MOP (2 mgjdose) (Sigma 
Chemical Co., St. Louis, MO) emulsified in an equal volume of FIA 
(Difco Laboratories, Detroit, MI). Group 5 received a water-in-oil 
emulsion made up of equal volumes of BASA and FIA. Group 6 received a 
combination of equal volumes of BASA and DDA ( Prolong™, Diamond 
Scientific, Des Moines, IA). Jugular blood samples were collected from 
all steers at the time of vaccination (day 0) and at intervals 
thereafter for serological assays (days 9, 14, 21, 28, 42, 56) and for 
the LP assay (days 3, 9, 14, 21, 28, 42, 56). 
Experiment ~. Thirty-four crossbred steers were allocated into 
nine groups. Group 1 (control, n=4) was not immunized. Group 2 (n=4) 
was vaccinated with the standard reduced dose of S19. Groups 3 (n=5) 
received BASA only. Group 4 (n=5) received BASA + heat-killed R..:,. 
acnes (obtained from ImmunoVet, Tampa, FL, (5 mg R..:_ acnesjdose). Group 
5 (n=5) received a solution of BASA + heat-killed ~ pertussis 
(Lederle Laboratories, Pearl River, New York, strain 130, (5 mg ~ 
pertussis/dose). Group 6 (n=5) received BASA + DDA as described in 
experiment 1. Group 7 (n=2) received R..:_ acnes alone, at the same dose 
as in group 4. Group 8 (n=2) received ~ pertussis only, at the same 
dosage as group 5. Group 9 (n=2) received 1 ml of DDA alone. Jugular 
blood samples were collected from all steers at the time of 
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vaccination (day 0) and at intervals thereafter for serological assays 
(days 6, 14, 21, 28, 42, 56) and for LP assay (days 4, 6, 11, 14, 21, 
28, 35, 42, 49, 56). 
described above. 
On day 35, the cattle were skin tested as 
Statistical analysis. Results were analyzed by the least 
significant difference (LSD) method (SAS, 1982). 
Results 
Serology. In the first experiment, the maximum number of steers 
positive by the CARD test was on days 14 and 21 (Table 1). By ELISA, 
an antibody response was det~cted in all groups by 9 days after 
vaccination (Fig. 1). In general, antibody responses for vaccinates 
peaked between days 28 and 56 as measured by ELISA and FIAX (Figs. 1 
and 2) and on day 14 as measured by the CF and RIV tests, with the 
exception that steers vaccinated with BASA + FIA reached a maximum 
antibody response on days 28, 42, and 56 by the RIV and CF tests 
respectively (Figs. 3 and 4). The mean serum antibody responses, as 
determined by the FIAX test and ELISA, were significantly higher (P < 
0.05) for vaccinates than for control steers at days 21, 42, and 56 
with FIAX and day 56 with ELISA. There were no significant differences 
(P > 0.05) between antibody responses for steers vaccinated with S19 
or with BASA + MOP. Mean antibody titers for BASA + MOP vaccinates 
were significantly higher (P < 0.05) than for BASA + DDA vaccinates on 
day 56 as measured by the FIAX and RIV tests. In many instances, 
antibody titers for S19 and BASA + adjuvant vaccinates were 
significantly (P <0.05) elevated over those for the steers that 
received BASA alone. By all serological tests, the highest mean titers 
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occurred in those groups receiving BASA + MDP and BASA + FIA. 
In the second experiment, the number of seropositive steers as 
determined by the CARD test reached a maximum by day 14 (Table 1) • 
Control steers and those receiving ~ acnes, !L.. pertussis, or DDA 
alone were consistently seronegative by all four serological tests. 
Overall, the maximum antibody responses for most groups occurred on 
day 56 (Figs. S-8). At that time, antibody responses for steers vacci-
nated with S19, BASA + !L_ pertussis, or BASA + DDA were significantly 
higher (P < 0.05) than for steers vaccinated with BASA alone or BASA + 
~ ~· As measured by the ELISA and the RIV test, S19 vaccinates 
had significantly higher antibody levels (P < 0.05) than did all other 
treatment groups on days 28 and 42. By all four serological tests, 
Sl9-vaccinated steers consistently had significantly higher titers 
than did control steers (P < 0.05) between days 14 and 56. There were 
no significant differences (P < 0. OS) in antibody responses between 
steers receiving BASA alone and BASA + ~ ~· Often mean antibody 
titers for the BASA + !L_ pertussis and BASA + DDA groups were 
significantly higher (P < 0.05) than for those receiving BASA alone or 
BASA + ~ ~· 
LP assay. For each sampling time, LP responses for both 
experiments were compared relative to responses in the control steers. 
Steers immunized with BASA alone had the lowest overall responses, in 
that the mean LP responses for those groups were substantially below 
day 0 values. 
In experiment 1, the LP responses of steers to HKA showed 
considerable individual variation with no consistent pattern in any of 
the groups (Fig. 9). The most distinct responses occurred from days 21 
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and 42, reaching a peak on day 42. The lowest LP responses in all 
groups occurred on day 14. Between days 21 and 42, LP responses for 
the BA5A + DDA groups were insignificantly elevated over the responses 
of BASA + MDP and BASA + FIA groups. On day 21, the LP responses for 
519, BA5A + MDP and BASA + DDA groups were significantly different (P 
<0. 05) from those for steers receiving BA5A alone. on day 42, the 
highest LP responses occurred in 519 vaccinates. Except for day 21, 
significant differences in LP responses were not seen among groups 
because of the small sample size per group (n = 5) and within group 
variations. 
In experiment 2, LP responses to HKA (20 ug/ml) for all groups 
were markedly elevated over control responses on days 4 and 21 (Fig. 
10). This was followed by a decline with only insignificant (P > 0.05) 
sporadic increases in group means .• In general, LP responses in the Sl9 
group were higher than for other treatment groups. LP response in the 
BA5A + DDA group reflected a similar pattern of response as in the S19 
group. Overall, Sl9 vaccinates had consistently higher LP responses 
than did control steers. DDA alone elicited markedly elevated LP 
responses which, in most instances, equaled or exceeded responses in 
Sl9 vaccinates (Fig. 11). However, as in experiment 1, significant 
differences were not observed among groups due to the small sample 
size and variation in LP responses within groups. 
Delayed ~ hypersensitivity. In experiment 2, steers in all 
groups were skin tested and two out of four S19-immunized, two out of 
five BA5A + DDA-immunized, and one out of five BASA + ~ ~ 
immunized steer had highly positive responses to BA5A. None of the 
steers in group 1 (control) or the other groups responded positively 
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to BASA. Overall, steers receiving BASA + DDA had the highest mean DTH 
response (Fig. 12). The least response was observed in steers 
receiving BASA alone. 
Discussion 
The capacity of various adjuvant preparations to augment both the 
cellular and humoral immune responses to experimental vaccine 
preparations have been documented (Bamford, 1980; Bamford, 1980; 
Edelman, 1980; Wells et al., 1982). A principal purpose for employing 
immunologic adjuvants is to elicit a more durable antibody and/or 
cell-mediated immune response by employing a smaller antigenic mass in 
a fewer number of doses. Adjuvants are also used to augment the 
induction of immunity against poorly or nonimmunogenic tumor cells or 
cells infected with intracellular microbes (g.g., Brucella) that are 
not adequately destroyed by naturally induced immune responses (Ribi, 
1986). In this study, we attempted to potentiate the immune response 
to a soluble antigen (BASA) by employing different adjuvants. A 
single administration of antigen was used to study the primary 
response in comparison to the single inoculation with S19 as a 
standard. There was marked variability in the ability of different 
adjuvants to augment both humoral and cell-mediated immune responses 
when administered with BASA. 
In experiment 1, the greatest serum antibody responses to !L. 
abortus were induced by BASA in conjunction with the adjuvants FIA and 
MDP. Steers receiving BASA + DDA had antibody responses of a 
magnitude intermediate between S19-vaccinated and control steers. FIA 
appeared to provide the greatest stimulus for antibody production. 
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Cell-mediated immune responses as determined by LP assay was most 
evident in Sl9 and BASA + DDA vaccinates, with the highest responses 
occurring in Sl9 vaccinates. Although MDP and FIA induced high 
antibody titers, they failed to stimulate LP responses at levels 
equivalent to Sl9-vaccinated cattle. DDA appeared to be the most 
efficacious adjuvant with respect to induction of LP responses. 
In experiment 2, the Sl9 group had the highest immunologic 
responses, i.e., antibody titers, LP response, and DTH responses. 
Among the adjuvant groups, BASA + DDA elicited the greatest CMI 
response as measured by LP and DTH tests. However, steers receiving 
DDA alone had marked LP responses on sporadic days, especially on day 
4 indicating nonspecific stimulation of LP responses may have 
occurred. 
In most instances, antibody responses for steers receiving BASA + 
~ pertussis were higher than those receiving BASA + DDA. Generally, 
antibody responses of the BASA + ~ ~ group were similar to those 
immunized with BASA alone. Increases in mean antibody titers persisted 
up to 56 days. 
The LP responses in the BASA + ~ ~ and BASA + ~ pertussis 
groups were often comparable to those of the BASA + DDA groups. 
However, the former groups failed to respond in the DTH test as did 
the latter group. In both experiments, humoral and CMI responses were 
lowest when no adjuvant was included with the antigen. On the basis of 
serological, LP and DTH results, DDA seemed to be the most effective 
adjuvant. 
Our results indicate that DDA promotes a marked CMI response with 
a low antibody response. DDA is a synthetic lipophilic quartenary 
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amine and a cationic surface-active lipid. The adjuvanticity and 
biological properties of DDA have been extensively reviewed (Baechtel 
and Prager, 1982; Chiba and Egashira, 1978; Gordon et al., 1980; 
Snippe et al., 1977; Snippe et al., 1982). One advantage of DDA over 
other adjuvants, especially those of microbial origin, is that it has 
no immunogenic components that might cross-react with ~ abortus 
(Corbel, 1985). DDA has been shown, in mice, to be effective in the 
immunopotentiation of Listeria sp. vaccines and also superior to 
Freund's complete adjuvant in stimulating a DTH reaction in mice 
(Snippe et al., 1977; VanderMeer et al., 1979). Woodard et al (1980) 
failed to potentiate acquired resistance to Brucella in guinea pigs 
using a DDA-~ abortus strain 45/20 vaccine. However, the dose of DDA 
used in that study may have caused deterioration of cellular integrity 
and lysis leading to lack of antigen processing (Prager, 1985). 
Development of an improved and effective nonliving 1L.. abortus 
vaccine would constitute major progress toward the goal of eradicating 
bovine brucellosis in the United States. These studies demonstrated 
that, in cattle, DDA stimulates both humoral and CMI responses when 
administered with a nonliving .!L_ abortus antigen preparation. 
Evaluation of DDA as an adjuvant for a Brucella vaccine using purified 
~ abortus antigens requires further study. 
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TABLE 1. Numbers of serologically positive cattle as detected by the 
Brucella abortus CARD test. 
Days after vaccination 
No. of {No. seroQositive} 
Group Vaccine Cattle 0 6 9 14 21 28 42 56 
ExQeriment fi 
1 None (control) 5 0 NDa 0 0 0 0 0 0 
2 S19 5 0 ND 4 5 5 5 5 5 
3 BASA 5 0 ND 2 2 1 1 1 1 
4 BASA + MDP 5 0 ND 5 5 5 5 5 5 
5 BASA + FIA 5 0 ND 4 5 5 5 4 5 
6 BASA + DDA 5 0 ND 4 3 4 3 2 1 
ExQeriment .t£12 
1 None (control) 4 0 0 ND 0 0 0 0 1 
2 S19 4 0 4 ND 4 4 4 4 4 
3 BASA 5 0 2 ND 4 3 1 3 3 
4 BASA + L. acnes 5 0 3 ND 4 2 1 4 3 
5 BASA + !L. Qertussis 5 0 5 ND 5 5 5 5 5 
6 BASA + DDA 5 0 2 ND 2 5 5 5 5 
7 L. ~only 2 0 0 ND 0 0 0 0 0 
8 !L. Qertussis only 2 0 0 ND 0 0 0 0 0 
9 DDA only 2 0 0 ND 0 0 0 0 0 
anot determined. 
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Figure 2. Mean antibody responses to ~ abortus 
in Experiment 1 as measured by a 
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Figure 5. Mean antibody responses to ~ abortus 
in Experiment 2 as measured by an 
enzyme-linked immunosorbent assay 
(ELISA). Antibody responses for 
steers receiving ~ acnes, ~ 
pertussis and DDA alone were 
similar to responses for steers in 
the control group. 
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Figure 6. Mean antibody responses to ~ abortus 
in Experiment 2 as measured by a 
fluorometric immunoassay (FlAX). 
Antibody responses for steers 
receiving ~ acnes, ~pertussis 
and DDA alone were similar to 









90 t-+- BASA 






42 49 56 
Figure 7. Mean antibody responses to~ abortus 
in Experiment 2 as measured by 
complement fixation (CF). Antibody 
responses for steers receiving ~ 
~' ~ pertussis and DDA alone 
were similar to responses for 
steers in the control group. 
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Figure 8. Mean antibody responses to ~ abortus 
in Experiment 2 as measured by 
Rivanol agglutination (RIV). 
Antibody responses for steers 
receiving ~ acnes, ~pertussis 
and DDA alone were similar to 
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CHAPTER III 
INFLUENCE OF IMMUNOMODULATORY AGENTS ON 
CELLULAR IMMUNE RESPONSES IN CATTLE 
VACCINATED WITH BRUCELLA ABORTUS 
SOLUBLE ANTIGEN 
Introduction 
Brucellosis continues to be a major worldwide problem from both 
economic and public health aspects (Matyas and Fujikura, 1984). 
Vaccination of heifers with strain 19 (S19) confers immunity against 
brucellosis and thereby helps control the disease. Despite the 
beneficial effects of S19, however, residual post-vaccinal antibody 
titers, aberrant serologic reactions, and chronic infections with S19 
may occur and interfere with routine diagnostic serologic tests 
(Corner et al., 1981; Sutherland et al., 1982). These problems have 
stimulated interest in development of an effective Brucella abortus 
vaccine that would induce protective immunity but would not have the 
problems associated with S19 (Alton, 1977). 
It was postulated that protective immunity can be induced against 
bovine brucellosis using a non-living (subunit) vaccine with an 
appropriate adjuvant (Winter et al., 1983). Numerous investigators 
have tested various non-living (subunit) vaccines in experimental 
bovine brucellosis (Woodard and Jasman, 1981; Confer et al., 1987; 
62 
63 
Winter et al., 1988). Variable degrees of success were seen. The 
objectives of the present study were to: (1) evaluate in cattle the 
immunostimulatory effects of various adjuvants for use with non-living 
fl.:.. abortus antigens by comparing an in vitro correlate of cell-
mediated immunity (CMI); ( 2) evaluate functional subset activities 
involved in CMI responses with regard to helper T-cell activity, 
macrophage activation, and suppressor cell activity of lymphocytes 
from calves immunized with 819 vaccine or a soluble fl.:.. abortus 
extract. 
Materials and Methods 
Cattle. Thirty-four weanling crossbred beef steers, 
approximately 250 to 300 kg each, were used. These steers were 
obtained from herds that had no clinical signs of brucellosis and were 
serologically negative for fl.:.. abortus. They were transported to the 
Livestock Health Research Center in Hugo, Oklahoma, maintained on a 
bermuda grass pasture, and fed a protein supplement. Thirty-four 
crossbred steers were placed into nine groups (see Table 1). The dose 
and source of adjuvant are the same as previously described in Chapter 
II. Jugular blood samples were collected from all steers at the time 
of vaccination (day 0) and at intervals thereafter for Interleukin 1 
and 2 assays (days 6, 14, 21, 28, 35, 42, 42, 56) and for the LP and 
suppressor factor assays (days 4, 6, 11, 14, 21, 28, 35, 49, 56). 
Adjuvants. Three adjuvants were used: Bordetella pertussis, 
Proprionobacterium acnes and dimethyl dioctadecyl-ammonium bromide 
(DDA). The capacity of these adjuvants as immune enhancers have been 
documented in cattle and other species (Bamford, 1980a,b; Snippe et 
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al., 1982; Wells et al., 1982). 
Immunogens. Brucella abortus soluble antigen (BASA) was used as 
the vaccine antigen as previously described (Chapter II). 
Lymphoproliferation assay ..L..!!RJ... 
previously described (Chapter II). 
The LP was conducted as 
Delayed typg hypersensitivity CDTH). DTH was conducted as 
previously described (Chapter II). 
Preparation of culture supernates for IL-l and IL-2 assay. 
Bovine peripheral blood mononuclear cells (PBMC, 5 x 106 cells/ml) 
were cultured in 96-well microtiter plates (Costar, Cambridge, MA) as 
previously described (Chapter II). Cultures were treated in 
triplicate with concanavalin A (Con A, 10 ug/ml), heat-killed !L.. 
abortus antigen (HKA, 20 ug/ml), gamma-irradiated !L_ abortus antigen 
(GBA, 20 ugfml), or !L_ abortus soluble antigen (BASA, 40 ug/ml). 
After 48 hr. incubation in a humidified atmosphere containing 5% C02, 
the plates were centrifuged at 200 g for ten minutes. Culture 
supernatants were collected (50 ul and 75 ul for IL-l and IL-2 assays 
respectively) into microtiter plates and frozen at -135° c. 
Interleukin-1 Assay 
IL-l was assayed using an IL-l-dependent murine helper T cell 
line (Dl0.G4.1) (obtained from American Type Culture Collection, ATCC, 
Rockville, Maryland). These cells were maintained by allostimulation 
on mitomycin c-treated H-2b C57BL/6 splenocytes as previously 
described (Kaye et al., 1984). Culture supernatant fluids were 
replenished with 50 ul RPMI 1640 medium supplemented with 10% fetal 
bovine serum (FBS). Briefly, 2 x 104 Dl0.G4.1 cells/per well were 
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cultured with culture supernatant fluid in a microtiter plate format 
for 48 hrs. and then pulsed with 3H-TdR (1 uCi/well, specific activity 
= 30 mCi) for an additional 4 hrs. at which time the cells were 
harvested onto filter papers using a cell harvester (PhD, Cambridge 
Technology, Cambridge, MA) and radioactivity determined in a liquid 
scintillation counter (Packard, Downers Grove, IL.). The results were 
compared to serial titrations of a recombinant human IL-l-standard 
(obtained from Dr. Peter T. Lomedico, Roffman-LaRoche, Inc., Nutley, 
NJ). 
Interleukin-2 assay. IL-2 in culture supernatant fluid was 
assayed using bovine IL-2- dependent BT-2 cells (obtained from Dr. 
P.E. Baker, Immunex Corporation, Seattle, WA). These cells were 
originally isolated from a primary mixed lymphocyte reaction culture 
and has been shown to be dependent on IL-2 for continued growth in 
culture (Baker and Knoblock, 1982). The cells were maintained in 
culture in 6 well microtiter plates at 3. 3 x 104/well in Dulbecco' s 
modified Eagles medium (DMEM) supplemented with 10% FBS with 1 ug/ml 
Con A and 10 U /ml recombinant bovine ( rb) IL-2, (obtained from Dr. 
P.E. Baker, Immunex Corporation, Seattle, WA). The cells were 
passaged 2-3 times per week. The assay system used was an adaptation 
of the quantitative microtiter assay of Gillis, et al. (1978). BT-2 
cells were washed 3x in DMEM to remove residual rb IL-2. Briefly, 2 x 
103 BT2 (in 25 ul of DMEM and 75 ml of supernate sample) cells per 
well were cultured with supernatant fluid from PBMC which has been 
exposed to different stimuli in a microtiter plate format for 48 hours 
and then radiolabelled with 3H-TdR for 4 hours. Proliferative 
responses were determined by 3H-TdR uptake as described above and 
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compared to parallel controls in which rb IL-2 has been titrated. 
Suppressor Factor Assay 
Suppressor factor assays were performed in conjunction with the 
LP assay. Culture supernatant fluid (50 ulfwell) was collected from 
lymphocyte cultures after 6 days of incubation. The original wells 
were replenished with 50 ul of fresh media, RPMI 1640 medium 
supplemented with 50 ug/ml gentamicin. The harvested fluids were 
stored at -135° c until assay. Suppressor factors were assayed by 
inhibition of blastogenesis of peripheral blood mononuclear cells 
(PBMC) induced with suboptimal levels of concanavalin A, by a 
modification of the assay previously described by Nelson et al. 
( 1987). The Con A dose of 0. 5 ug/ml was determined by titrating PBMC 
from a Hereford steer with different doses of Con A and a suboptimal 
concentration was chosen for the suppressor assay according to a dose-
response curve. PBMC from this steer was used throughout the 
experiment to determine suppression. To assay the culture supernates, 
50 ul of RPMI 1640 medium supplemented with 10% FBS plus 50 ug/ml 
gentamicin was added to 50 ul of the sample and 100 ul of media 
containing 1 x 105 PBMC plus 0.5 ug of Con A was added to each well. 
After a 72 hr incubation each well was pulsed for 18 hr. with 0.8 uCi 
of 3H-TdR. The cells were harvested onto filter papers and thymidine 
incorporation determined as previously described. 
expressed as stimulation index. 
Results are 
Statistical analysis. Results were analyzed by the least 
significant difference (LSD) method (SAS, 1982). 




Data are shown as relative stimulation indices (RSI) and are 
expressed relative to the responses in the control steers. See 
Chapter II for the results and discussion of the LP and DTH responses. 
IL-l Production 
With the exception of minor variations, IL-l activity detected in 
supernatants from mitogen-/antigen-stimulated cultures reflected the 
same pattern of responses (Figures 1-4). The most distinct 
proliferative responses occurred in day 14 samples. This was followed 
by a decline with only insignificant (P > 0.05) sporadic increases in 
group means. On day 14, statistical analysis showed that IL-l levels 
for groups 6, 8, and 9 were significantly (P < 0.05) greater than the 
levels for the control and other treatment groups. Often IL-l levels 
for group 7 steers were insignificantly elevated (P > 0.05) over the 
control levels. The greatest and least stimuli for IL-l production 
were respectively induced by .BASA + DDA and 519. IL-l dependent cells 
proliferated minimally when stimulated directly with mitogen (Con A) 
or antigen (HKA, GBA, BASA) alone. This suggests that the cells were 
not responding to residual antigen or mitogen in the culture 
supernatant fluid but to a factor elaborated by the stimulated PBMC 
used to generate the supernates. 
IL-2 Production 
IL-2 activity in Con A-stimulated culture supernatant fluid 
demonstrated considerable variation with no consistent pattern in any 
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group (Figure 5) • The 519 group had a progressive rise in IL-2 
production from day 0 to day 28 followed by a plateau and decline. On 
day 35, IL-2 levels in all treatment groups were elevated over the 
control levels. At that time, steers receiving ~ acnes, .!2...:.. 
pertussis, and DDA alone had significantly higher (P < 0.05) IL-2 
levels than control steers. Except for minor variations, IL-2 
activity in supernatant fluids from antigen-stimulated PBMC was 
maintained at similar levels (Figures 6-8). Sl9 vaccinates had the 
greatest stimulus for IL-2 production which peaked on day 21. At that 
time, the 519 group had significantly (P < 0.05) greater IL-2 levels 
than levels for the other treatment groups. Steers receiving DDA 
alone had transient insignificant (P < 0.05) rises in IL-2 levels. 
IL-2 production in the Sl9 group corresponded with the results of the 
lymphoproliferative assay. BT-2 cells failed to proliferate when 
cultured with Con A or antigen alone indicating no effect of any 
possible antigen or mitogen carried over in the supernates from the 
generating cultures of PBMC. 
Suppressor Factor Assay 
Data for soluble suppressor factor release in response to 
stimulation with mitogen p.nd fL.. abortus antigens are illustrated in 
Figures 9-11. The group mean RSI to PWM and fL._ abortus antigens 
demonstrated a wide range of mean values. A non-significant (P > 
0.05) depression in responsiveness to PWM occurred at day 7 in all 
treatment groups (Figure 9). The largest suppressive responses to PWM 
were observed in BASA + fL._ pertussis and BASA + DDA vaccinates in that 
the mean RSI for these groups were lower than the controls on six of 
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eleven bleeding days. HKA induced suppressive supernates on days 14 
and 28 for all treatment groups (Figure 10) • This was followed by 
insignificant ( P > 0. OS) sporadic depressions in group means. 
Responses to HKA induced supernates in BASA + ~ pertussis vaccinates 
rebounded to above the control group at day 42 with a gradual increase 
in responsiveness to HKA. The largest HKA-induced suppressive 
supernates were observed in S19, BASA and ~ acnes vaccinated steers. 
GBA induced suppressive supernates in all treatment groups on day 7 
and in S19, BASA + DDA, .E.:_ acnes, ~ pertussis and DDA vaccinated 
steers on days 14 and 28. The largest GBA-induced suppressive 
supernates were observed in S19, BASA + ~ pertussis and ~ ~ 
vaccinated steers. 
Discussion 
Adjuvant-induced modulation of immune responses to several ~ 
abortus immunogens has been documented (Woodard et al., 1980; Winter 
et al., 1983; Montaraz and Winter, 1986; Confer et al., 1987; Winter 
et al., 1988). The mechanisms of actions of these adjuvants have not 
been clearly defined. Therefore in this study, we attempted to 
elucidate the basis for the mechanism of actions of adjuvants when 
administered with BASA by assaying for IL-l, IL-2, and soluble 
suppressor factor release in supernatant fluids from mitogens or ~ 
abortus antigen-stimulated PBMC cultures. 
Cell-mediated immune responses require interactions between 
immunocompetent cells and soluble factors. One- of these factors is 
IL-2 (T-cell growth factor). IL-2, a glycoprotein produced by 
lymphocytes in response to antigenic or mitogenic stimulation sustains 
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the clonal expansion of activated T-cells, activates natural killer 
cells, enhances thymocyte mitogenesis, and induces cytotoxic T-cell 
activity (Magnuson, et al, 1987). Reduced IL-2 production is an 
important mechanism in pathogenesis of infectious disease (Wainberg et 
al., 1983; Orz et al., 1985; Modlin et al., 1984). The ability of an 
individual's lymphocytes to produce and respond to IL-2 may provide a 
quantitative measure of CMI responses to specific antigens (Miller-
Edge and Splitter, 1986). In the present study, 819 provided the 
greatest stimulus for IL-2 production. For the BASA plus adjuvant 
groups, none of the lymphocyte cultures produced IL-2 in response to 
~ abortus antigens at levels equivalent to those for S19-vaccinated 
cattle. However, Con A-stimulated cells from each group produced 
equivalent IL-2 levels. 
IL-2 production in 819-vaccinated cattle corresponded with the LP 
responses. Although the LP responses in BASA + DDA vaccinated cattle 
reflected a similar pattern as in S19 vaccinates, the former did not 
produce equivalent levels of IL-2. The reason for this disparity is 
not known. To exert its biological effects, IL-2 must interact with 
high affinity receptors on the lymphocyte membranes (Fletcher and 
Goldstein, 1987). Therefore, IL-2 levels measured by this assay 
system, reflect only the amount of free IL-2 in the supernatant fluid. 
Perhaps, the presence of an inhibitory factor in culture supernatants 
could have blocked IL-2 activity in the culture fluids (Lafferty et 
al., 1980). Proliferation of bovine PBMC is dependent on the presence 
of IL-2. The fact that LP responses in the BASA + DDA group 
paralleled responses in the Sl9 group suggests that low IL-2 levels in 
culture supernatants from BASA + DDA vaccinated cattle may be due to 
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the amount of IL-2 consumed by activated T-cells, rather than the 
presence of inhibitory factors in the medium. 
Macrophages are important in the induction and expression of the 
immune response through direct cellular interactions and by production 
of monokines such as IL-l (lymphocyte activating factor). IL-l 
modulates many of the responses involved in the process of host 
defense against infection. IL-l acts as an endogenous adjuvant, 
serving as a co-factor during lymphocyte activation primarily by 
inducing the synthesis of IL-2 and the activation of the resting T 
cell (Staruch and Wood, 1983). In the present study, DDA provided the 
strongest stimulus for IL-l production. 
production was seen in the Sl9 group. 
observed in groups 4 and 5. 
The least stimulus for IL-l 
Marginal levels of IL-l were 
The low level of IL-l observed in the S19 group was unexpected 
because LP responses and IL-2 production were greatest in that group. 
Several factors may account for this. As with other polypeptide 
hormones, IL-l exerts its biological effect on target cells by first 
binding to specific cell surface receptors. Several cell types 
express receptors for and are IL-l responsive (Dower and Urdal, 1987). 
Lymphocytes from S19 vaccinated cattle may have had a greater 
responsiveness for IL-l leading to increased consumption of IL-l in 
the culture medium. IL-l is expressed in both secreted and membrane-
associated form in macrophage, monocytes, and B cell cultures 
(Oppenheim, 1986; Kurt-Jones et al., 1985). Recently, Splitter and 
Ever lith ( 1989) demonstrated that !L.. abortus induces production of 
both membrane and secreted forms of IL-l from macrophages. As a 
membrane-associated molecule, membrane IL-l may serve as a persistent, 
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localized stimulant to activated T cells when present on the surface 
of antigen presenting cells at a site of infection (Oppenheim, 1986). 
It is, therefore, possible that PBMC from the 519 group preferentially 
express membrane IL-l rather than secreted IL-l. 
A variety of products of microbial origin can modulate the immune 
system (Schwab, 1977) and some bacterial agents can suppress various 
phases of specific immunity (Schwab, 1983). A decreased LP response 
to phytohemagglutinin was reported in humans with acute and chronic 
brucellosis (Renoux and Renoux, 1977). Inhibition of the LP response 
to several mitogens was described in experimental murine brucellosis 
(Riglars and Cheers, 1980). Furthermore, immunomodulatory agents may 
produce variable effects on the immune system from immunostimulation, 
immunosuppression, or no effect (Bizzini, 1984). In the present 
study, soluble suppressor factors were demonstrated in culture 
supernatant fluids from PBMC stimulated with PWM and IL.. abortus 
antigens. The least and greatest depressions in LP responses were 
seen in culture supernatants from PWM and antigen-stimulated 
lymphocytes respectively. The greatest suppressive responses were 
observed in groups 2, 5, and 7. The suppressive effects may be due to 
the effect of the adjuvant, because steers receiving adjuvants had 
depressed LP responses. However, we could not demonstrate a direct 
correlation between LP responses and the suppressive effect of culture 
supernatants. 
The choice of an adjuvant for any vaccine should be determined by 
the relative role of humoral and cell-mediated immunity required for 
protecting the host against the infectious agent. In this study, DDA 
proved to be the most efficacious adjuvant with respect to CMI 
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responses i.e. increased LP and DTH responses (Chapter II), increased 
IL-l production and decreased soluble suppressor factor production. 
DDA enhances macrophage and T-lymphocyte functions and reduces 
suppressor T-cell function (Gordon et al., 1980; Kraaijeveld et al., 
1982). However, we were unable to demonstrate that DDA enhanced IL-2 
production. The stimulatory effect of DDA on macrophages may be 
particularly important because .§....:_ abortus is an intracellular 
pathogen, and macrophages may be important in host defense in bovine 
brucellosis (Braude, 1951). The results obtained for~ acnes and~ 
pertussis were unexpected. These adjuvants failed to induce CMI 
responses comparable to DDA. These adjuvants are both potent 
stimulators of CMI responses (Bomford, 1980; Warren, 1986). Recently, 
it was demonstrated that ~ ~ administered with Sl9 vaccine 
potentiates CMI responses in guinea pigs (Panangala et al., 1986). 
The effective dose of those adjuvants for use in cattle may need to be 
investigated. 
The search for immune modulators is an important area of 
investigation because of the increased emphasis on the use of subunit 
vaccines. Numerous microbial-derived and synthetic compounds have 
been described to enhance humoral or cellular immune responses in 
animals (Edelman, 1980). Successful application of adjuvants to 
subunit vaccines will depend on the understanding of the mechanisms of 
action of the adjuvant and the appropriate factors and segments of the 
immune system that must be stimulated. 
Table I 
VACCINE AND ADJUVANT PREPARATIONS ADMINISTERD TO EACH 















BASA + P. acnesC 
BASA + B. p;;t;ssisd 
BASA + DDAe 
~ acnes only 
~ pertussis only 
DDA only 
a Standard reduced dose (1 x 109 CFU) 
b 2 mg protein 
c 5 mg ~ acnes 
d 5 mg ~ pertussis 
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Figure 1. Mean relative stimulation indices to 
Con A-induced IL-l production in 
culture supernatant fluid on day 
14. The vaccine and adjuvant 
preparations administered to each 
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Figure 2. Mean relative stimulation indices to 
heat-killed B. abortus-induced IL-l 
production in culture supernatant 
fluid on day 14. The vaccine and 
adjuvant preparations administered 
to each group of animals are shown 
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Figure 3. Mean relative stimulation indices to 
gamma-irradiated B. abortus-induced 
IL-l production in culture 
supernatant fluid on day 14. The 
vaccine and adjuvant preparations 
administered to each group of 
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BASA-induced IL-l production in 
culture supernatant fluid on day 
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Figure 6A, B. Mean relative stimulation indices to heat killed ~ abortus-induced IL-2 production in 
culture supernatant fluid. The vaccine and adjuvant preparations administered to each 
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Figure 7A, B. Mean relative stimulation indices to gamma-irradiated ~ abortus-induced IL-2 production in 
culture supernatant fluid. The vaccine and adjuvant preparations administered to each group 
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CHAPTER IV 
IMMUNOPOTENTIATION OF CATTLE VACCINATED WITH A 
SOLUBLE BRUCELLA ABORTUS ANTIGEN WITH LOW 
LPS CONTENT: AN ANALYSIS OF CELLULAR 
AND HUMORAL IMMUNE RESPONSES 
Introduction 
Bovine brucellosis caused by Brucella abortus is an economically 
important disease associated with abortion and infertility resulting 
in substantial economic loss to cattle producers. Despite numerous 
methods of eradication, including vaccination, and test and slaughter, 
the disease has remained prevalent in many areas of the world 
(Sutherland, 1980; Matyas and FUjikura, 1984). 
Vaccination of cattle with attenuated ~ abortus strain 19 (S19) 
provides protection from abortion. However, S19 vaccine can cause 
some cattle to become seropositive, induce persistent infection and 
interfere with the interpretation of routine serologic diagnostic 
tests (Morgan, 1977; Sutherland et al., 1982). The problems currently 
associated with S19 vaccine have generated interest in the development 
of a subunit ~ abortus vaccine which contains antigens essential only 
for stimulation of immunity. 
Generally, non-living (subunit) vaccines can be weakly 
immunogenic and require adjuvants to enhance their immunogenicity. 
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Several researchers have examined the efficacy of vaccines to protect 
laboratory animals and cattle against experimental brucellosis 
(Woodard and Jasman, 1983; Winter et al., 1983; Montaraz and Winter, 
1986; Confer et al., 1987; Winter et al., 1988). 
We have previously reported that DDA stimulates increased CMI 
and low humoral immune responses in cattle when administered with BASA 
(Chapter II and III). The purposes of these studies reported herein 
were to attempt to enhance immune responses in cattle to a non-living 
~ abortus antigen preparation by a combination of different adjuvants 
and to evaluate the immunoenhancing effects of these adjuvants through 
analysis of serum antibody and cell-mediated immune (CMI) responses. 
Specific aspects of induced CMI responses investigated were 
macrophage activation (IL-l production), T-helper cell (IL-2 
production), and suppressor cell activity. 
Materials and Methods 
Cattle 
Thirty-five weanling crossbred beef steers approximately 250 to 
300 kg each were used. These steers were obtained from herds that had 
no clinical signs of brucellosis and were serologically negative for 
~ abortus. They were transported to the Livestock Health Research 
Center in Hugo, Oklahoma, maintained on a bermuda grass pasture and 
fed a protein supplement. 
Antigen for Vaccines 
The vaccine antigen (GBASA) was a soluble extract of gamma 
irradiated ~ abortus 19 (GBA) and referred to as GBASA. GBASA was 
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used because it appeared to contain fewer denatured protein antigens 
than BASA (J.H. Wyckoff, unpublished data). Briefly, 1 gm of sterile, 
lyophilized GBA was rehydrated with 10 ml of distilled water and 
further diluted with 10 ml PBS (O.OlM Po4 , 0.15M NaCl). 5 ml portions 
of the bacterial suspension was run through a French pressure cell for 
10 minutes at 20,000 PSI. Supernatant aliquots were pooled and ultra 
centrifuged (30,000 g, 1 hr.) at 4° c. Proteins were precipitated 
from the supernatant with 70% saturated ammonium sulfate stirred 
overnight at 4° C and then washed with 70% saturated ammonium sulfate 
with centrifugation (30,000 g, 1 hr.) at 4° c (Sorval RC5C, Dupont). 
The precipitate was solubilized in PBS and dialyzed against PBS ( 5 
changes of PBS) with a 2000 kDa exclusion dialysis membrane. GBASA 
contained (2.78 mgjml of protein) (Bradford, Bio-Rad) and 0.147 ug of 
2-keto-3 deoxyoctulosonic acid (KDO) per mg of protein (Warren, 1956). 
Lymphoproliferation i1£l Assay 
The LP assay, using peripheral blood mononuclear cells (PBMC) 
separated on Ficoll-hypaque, was essentially the same as previously 
described (Chapter II) • Antigens used were heat-killed !h. abortus 
(HKA, 2 ugjwell) and GBA (2 ugjwell). Pokeweed mitogen (PWM) was used 
as a positive stimulation control. 
Serologic Tests 
The standard serologic tests used were the brucellosis card test 
(CARD), rivanol precipitation-plate agglutination test (RIV) and a 
microtiter complement fixation test (CF) (Alton, et al, 1975). 
A quantitative fluorometric immunoassay [Fluorescent Immunoassay 
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System (FIAX) Whittaker M.A. Biologics] was performed as previously 
described (Hallet al., 1984). 
The enzyme-linked immunosorbent assay (ELISA) was performed as 
previously described (Confer et al., 1985) except that the antigen was 
GBASA (6 ugjml). 
Delayed-type Hypersensitivity 
As an in vivo correlate of CMI, the delayed-type hypersensitivity 
(DTH) to GBASA was performed 35 days after vaccination, as 
previously described (Chapter II) except that increases in skin fold 
thickness were measured 24 hours after the initial injection of 
antigen or saline. An increase in double skin fold thickness of 2 mm 
or greater than the initial measurement prior to injection of antigen 
was considered as a positive reaction (Nicolleti, 1983). 
Assays for Interleukin-1 {IL-l), Interleukin-2 
(IL-2), and Other Immunomodulatory Factors 
Collection of culture supernatant fluids and assays for IL-l and 
IL-2, and immunomodulatory factors were performed as previously 
described (Chapter III). For the suppressor factor assay, a 
suboptimal dose of Con-A at 1 ugfml was used as determined from a 
dose-response curve. 
Adjuvants 
The adjuvants used were trehalose dimycolate {TDM, Ribi 
Immunochem Research, Inc., Hamilton, Montana), muramyl dipeptide (MDP, 
Sigma Chemical Co., St. Louis, MO), and dimethyl dioctadecyl ammonium 
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bromide (DDA) (Prolong, kindly provided by Diamond Scientific Co., Des 
Moines, IA) . 
Experimental Design 
Two mg of GBASA (2 mg protein/ml) was mixed with an equal volume 
of the relevant adjuvant or sterile PBS. A single vaccine was 
injected subcutaneously in the cervical region anterior to the scapula 
on day 0. The 35 steers were randomly allotted into nine groups 
(Table 1). Group 1 (control, n=S) was not vaccinated. Group 2 (n=4) 
was vaccinated with the standard reduced dose of S19, 1 x 109 colony 
forming units (CFU). Group 3 ( n=5) received GBASA only ( 1 ml per 
dose). Group 4 (n=5) received GBASA and DDA. Group 5 (n=5) received 
GBASA + DDA + MDP (2 mgfdose). Group 6 (n=5) received GBASA + DDA + 
TDM (2 mgfdose). Group 7 (n=2) received DDA + MDP (2 mgfdose). 
Groups 9 (n=2) received DDA + TDM (2 mg/dose). Jugular blood samples 
were collected from all steers at the time of vaccination (day 0) and 
sequentially thereafter for serological assays (days 7, 14, 21, 28, 
35, 42, 49, 56), LP and suppressor factor (days 3, 7, 10, 14, 21, 28, 
35, 42, 49, 56) and for interleukin 1 and 2 assays (days 7, 14, 28, 
56). 
Data for the LP assay, IL-l, IL-2, and suppressor factor 
production are shown as relative stimulation indices (RSI) and are 
expressed relative to the responses in the control steers. RSI = 
stimulation index of experimental group/stimulation index of control 
group. For the suppressor factor assay RSI values below group 1 
values indicate suppression. 
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Statistical Analysis 
All data, except DTH responses, were compared among groups using 
the least significant difference (LSD) method (SAS, 1982). The means 
for DTH responses were analyzed by Students t-tests (Bailey, 1981). 
Statistically significant differences were considered where P < 0.05. 
Results 
Serology 
The number of seropositive steers as determined by the CARD test 
reached a maximum on day 14 and declined thereafter except for S19 
vaccinates (Table 1). The mean antibody responses measured by all 
four serological tests are shown in Figs. 1-4. Unvaccinated controls 
and steers receiving DDA, DDA + MDP, or DDA + TDM remained 
seronegative by all four serological tests throughout the experiment. 
In general, the highest mean titers for the GBASA vaccinated groups as 
measured by all serologic assays was on day 14 (Figs. 1-4). By all 
four serological tests, S19-vaccinated steers consistently had 
significantly higher titers (P < 0. OS) than all treatment groups 
between days 14 and 56. As measured by the FIAX and ELISA, GBASA + 
DDA, GBASA + DDA + MDP, and GBASA + DDA + TDM vaccinates had 
significantly elevated (P < 0.05) antibody titers over control steers 
on days 21 and 28. There were no significant differences in antibody 
titers among GBASA + DDA, GBASA + DDA + MDP, and GBASA + DDA + TDM 
vaccinates. As measured by the RIV, antibody titers for GBASA + DDA 
and GBASA + DDA + TDM vaccinates were significantly higher (P < 0.05) 
than for steers vaccinated with GBASA alone on days 14 and 21. On day 
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14 as measured respectively by the ELISA and FIAX, antibody titers for 
GBASA + DDA + TDM vaccinates and GBASA + DDA + MDP vaccinates were 
significantly higher (P < 0.05) than for steers receiving GBASA alone. 
Lymphoproliferation assay ibf1 
The LP responses to HKA and GBA were highly variable with no 
consistent pattern in any of the groups (Figs. 5 and 6). LP responses 
to HKA in all groups were greater than the control responses on days 
0 , 7 , 21 , and 3 5 . With the exception of DDA + MDP vaccinates, LP 
responses to HKA for GBASA + DDA + TDM vaccinates were significantly 
elevated (P < 0.05) over all treatment groups on day 35. Overall, LP 
responses to HKA and GBA were most pronounced in GBASA + DDA + TDM 
vaccinates. With the exception of days 28 and 42, LP responses to GBA 
for all treatment groups were generally greater than the control 
responses. With the exception of GBASA and GBASA + DDA vaccinates, LP 
responses to GBA gradually increased above the control responses after 
day 42 (Fig. 6). LP responses to GBA for steers receiving DDA alone 
were significantly different (P < 0.05) from the control responses on 
day 35. 
Delayed IYPg Hypersensitivity 
On day 35 two steers in 519 and GBASA + DDA + TDM, and 1 steer in 
GBASA, GBASA + DDA, and GBASA + DDA + MDP vaccinated steers had a 
positive reaction to GBASA by the DTH test. Also the mean DTH 
responses for 519, GBASA, GBASA + DDA + MDP and GBASA + DDA + TDM 
vaccinates were significantly higher (P < 0.05) than the control 
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(group 1) responses. However, the responses for 519, GBA5A + OOA + 
MOP, and GBA5A + DOA + TOM vaccinates were not significantly different 
from responses for steers receiving GBA5A alone. Overall, steers 
receiving 519 had the highest mean OTH response (Fig. 7). 
IL-l and IL-2 Production 
The IL-l levels in culture supernatants for all groups were 
insignificantly elevated over the control levels (group 1) on day 7 
(Figs. 8-10). This was followed by a decline and insignificant 
sporadic increases in group means. On day 7, 519 appeared to provide 
the greatest stimulus for IL-l production. IL-l levels for the Sl9 
group were consistently lower than group 1 levels on day 14 followed 
by a gradual increase in IL-l activity. There was a marked 
variability in IL-l activity in culture supernatants from steers 
receiving adjuvants alone. However, IL-l activity appeared most 
pronounced in culture supernatant from OOA + TOM vaccinates. con A-
induced IL-l production for 519, GBA5A + OOA, and GBA5A + OOA + TOM 
was significantly higher (P < 0.05) than IL-l production in group 1 
steers in day 56. overall, IL-l production was greatest in 519 and 
GBA5A + OOA vaccinates. 
Con A-, HKA-, and GSA-induced IL-2 production was highly variable 
with no consistent pattern in any of the groups. There was an initial 
rise in IL-2 levels over the unvaccinated controls (group 1) on day 0, 
which generally declined below control levels on days 7 and 14, and 
thereafter gradually increased above the control levels to day 56 
(Figs. 11-13). As measured by relative stimulation indexes, Con A-
induced IL-2 activity peaked on day 28. At that time, IL-2 activity 
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in groups 2-7 steers was significantly greater (P < 0.05) than the IL-
2 activity for controls (group 1). HKA- and GSA-stimulated cultures 
induced minimal levels of IL-2 activity in that the RSI for all 
treatment groups were substantially below day 0 values (Figs. 12 and 
13). However, there was a gradual non-significant rise in IL-2 levels 
above the control levels after day 14. Overall, the greatest IL-2 
levels were observed in S19 and GSASA + DDA + TDM vaccinates. 
Production of Immunomodulatory 
Factor(s) 
Culture supernatant fluid from HKA- and GSA-stimulated 
lymphocytes did not appear to inhibit Con A-induced blastogenesis of 
normal PSMC as the mean RSI for all groups were generally greater 
than the mean RSI of the controls (Figs. 22-2 5). The mean 
proliferative responses for groups 2-6 to HKA-stimulated supernatant 
fluid were significantly greater (P < 0.05) than the control responses 
on day 3. On day 21, the mean RSI for proliferative responses in GSA-
generated culture supernatant for group 2 was significantly higher (P 
< 0.05) than the control responses. Stimulation of PSMC from group 6 
steers with GSA induced suppressive supernatants on days 3 and 56. 
Discussion 
The development of a subunit vaccine for bovine brucellosis for 
replacement of S19 is an important research objective in several 
laboratories worldwide. The success of a subunit ~ abortus vaccine 
will depend on the ability of the vaccine components to stimulate an 
effective host immune response. Several investigators have examined 
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the immunogenicity of surface proteins of ~ abortus (Winter et al., 
1983; Confer et al., 1987; Winter et al., 1988; Winter and Rowe, 
1988). However, the composition of a potential subunit vaccine has yet 
to be determined (Winter et al, 1983). 
In the present study, we evaluated the serum antibody and CMI 
responses to GBASA given in combination with various adjuvants. A 
single administration of antigen was used to study the primary 
response in comparison to the single inoculation with S19 as a 
standard. Adjuvants were selected which enhance cell-mediated as well 
as humoral immune responses (Winter et al., 1983; Snippe et al., 1982) 
and the combination of TOM and MOP (Woodard, 1981; Winter et al., 
1983) induced cell-mediated immune responses to ~ abortus antigens in 
cattle. Previously, we demonstrated that OOA + BASA stimulates CMI 
responses in cattle. We, therefore attempted to further enhance this 
response by the addition of MOP or TOM (known potentiators of CMI 
responses) to OOA. 
GBASA contains S-LP8 (but a reduced content compared to BA8A) as 
evidenced by the development of positive standard serological tests. 
The highest and most sustained serum antibody responses to ~ abortus 
were elicited by 819 vaccine. Steers receiving GBASA adjuvanted 
vaccines had antibody responses of a magnitude intermediate between 
819-vaccinated and control steers. Humoral responses were lowest when 
no adjuvant was included with the antigen. A combination of OOA + TDM 
with GBASA induced higher serum antibody titers than OOA + GBASA 
alone. However, titers declined markedly by day 28, therefore 
suggesting that a mere transient response to LP8 can be induced by a 
subunit of ~ abortus in combination with adjuvants. 
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The CMI response as determined by the LP and DTH was highest 
among GBASA + DDA + TDM and Sl9 vaccinates. This indicates that the 
addition of TDM to DDA enhanced classical CMI responses. A rise in LP 
responses to PWM and GBA was observed in all groups after the DTH 
test, suggesting an anamnestic CMI response to the previous antigenic 
stimulation. 
Cells from Sl9 vaccinated steers had the greatest IL-l 
production. For groups 4, 5, and 6, IL-l production was most evident 
in the GBASA + DDA group. IL-2 production was most evident in 519 and 
GBASA + DDA + TDM vaccinated steers similar to that of the LP and DTH 
responses. Lymphocyte cultures from group 6 steers stimulated with 
GBA induced suppressive supernates on days 3 and 56. 
In the present study, DDA and a combination of DDA + TDM proved 
to be most effective with respect to enhancing CMI responses to GBASA, 
i.e. increased IL-l production (GSASA + DDA) and increased LP and DTH 
responses and IL-2 production (GSASA + DDA + TDM). Within groups, 
there were marked variations in LP responses to HKA and GSA. Other 
researchers have (Rossi et al., 1978; Jones, 1981) demonstrated 
inconsistency in lymphocyte reactivity to .§...:.. abortus antigen 
preparations. IL-l production in HKA and GSA-stimulated cultures were 
generally low even in Sl9 vaccinates compared to the results obtained 
in the previous study (Chapter III). Recently, Splitter and Everlith 
(1989) demonstrated that in macrophages .§...:.. abortus induces the 
production of both membrane IL-l and secreted IL-l. It is therefore 
possible that cells used in the lymphocyte cultures preferentially 
express membrane IL-l rather than secreted IL-l, the latter which was 
measured by our assay system. HKA- and GSA-induced IL-2 production 
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were substantially below day 0 values. The reason for this is not 
known. Perhaps, the presence of an inhibitory factor in culture 
supernatants could have blocked IL-2 activity in the culture fluids 
(Lafferty et al., 1980). Generally, soluble suppressor factor(s) was 
not detected in lymphocyte cultures from cattle immunized with GBASA 
adjuvanted vaccines. This could be due to the low content of LPS in 
GBASA; LPS has been shown to down regulate lymphokine production and 
T-cell responses (Steeg et al., 1982). 
OOA enhances macrophage function and T-lymphocyte functions and 
reduces suppressor T-cell function (Gordon et al., 1980; Kraaijeveld 
et al., 1982; Prager, 1985). The stimulatory effect of OOA on 
macrophages may be particularly important because !L_ abortus is an 
intracellular pathogen and macrophages are believed to be important in 
host defense in bovine brucellosis (Splitter and Everlith, 1986). TOM 
\ 
increa~ed the immunogenic potency of non-viable vaccines against a 
variet;\ of killed microorganisms such as !L_ abortus (Woodard et al., 
1980). In vitro, TOM can stimulate proliferation of T-cells 
(Kierszenbaum et al., 1981). The observed effects of many adjuvants 
are secondary to their action on macrophages as a target and mediator 
cell (Unanue et al., 1969; Allison, 1979; Osebold, 1982). Many agents 
exert their adjuvant effects by inducing the release of IL-l from 
macrophages (Genounou et al., 1985; staruch and Wood, 1983; Oppenheim 
et al., 1980). Adjuvants also stimulate the proliferation and 
differentiation of immunocompetent cells. IL-l released from 
macrophages, enhances the release of IL-2 from T-cells; IL-2 would in 
turn enhance the proliferation of those T-helper cells that recognize 
bacterial antigens (Oinarello, 1984). 
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These studies demonstrated that a combination of DDA + TDM 
potentiates CMI responses to a nonliving, soluble ~ abortus antigen 
preparation and may be useful as adjuvants for future vaccines, 
particularly subunit vaccines. 
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TABLE 1. Numbers of serologically positive cattle as detected by the 
Brucella abortus CARD test. 
Days after vaccination 
(No. seroQositive) 
Group ( n) Vaccine 0 7 14 21 28 35 42 49 56 
1 ( 5) None (control) 0 0 0 0 0 0 0 0 0 
2 ( 4) 519 0 4 4 4 4 4 4 4 4 
3 ( 5) GBASA 0 3 3 0 0 0 0 0 0 
4 (5) GBASA + DDA 0 1 4 4 2 3 1 1 1 
5 ( 5) GBASA + DDA + MOP 0 2 4 4 2 4 1 1 1 
6 ( 5) GBASA + DDA + TOM 0 4 5 5 4 5 0 1 0 
7 (2) DDA only 0 0 0 0 0 0 0 0 0 
8 ( 2) DDA + MOP (only) 0 0 0 0 0 0 0 0 0 
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Figure 1. Mean antibody responses to ~ abortus 
as measured by complement fixation 
(CF). Antibody responses for 
steers receiving DDA, DDA + MDP and 
DDA + TDM alone were similar to 
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Figure 2. Mean antibody responses to ~ abortus 
as measured by Rivanol 
agglutination (RIV). Antibody 
responses for steers receiving DDA, 
DDA + MDP and DDA + TDM alone were 
similar to responses for steers in 
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Figure 3. Mean antibody responses to ~ abortus 
as measured by an enzyme-linked 
immunosorbent assay (ELISA). 
Antibody responses for steers 
receiving DDA, DDA + MDP and DDA + 
TDM alone were similar to responses 
for steers in the control group. 
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Figure 4. Mean antibody responses to ~ abortus 
as measured by a fluorometric 
immunoassay (FlAX). Antibody 
responses for steers receiving DDA, 
DDA + MDP and DDA + TDM alone were 
similar to responses for steers in 
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Figure 8A, B. Mean relative stimulation indices to Con A-induced IL-l production in culture supernatant 
fluid. The vaccine and adjuvant preparations administered to each group of animals as 
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Figure 9A, B. Mean relative stimulation indices to heat-killed ~ abortus-induced IL-l production in 
culture supernatant fluid. The vaccine and adjuvant preparations administered to each 
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Figure lOA, B. Mean relative stimulation indices to gamma-irradiated ~ abortus-induced IL-l production in 
culture supernatant fluid. The vaccine and adjuvant preparations administered to each 
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Figure llA, B. Mean relative stimulation indices to Con A-induced IL-2 production in culture 
fluid. The vaccine and adjuvant preparations administered to each group of 












> ... ... 
~ 
00 7 
Figure 12A, B. 
!5 
- COI/TIIOL 
---Ill i - COOITl'IOL -6- IDA 
-+- IIIIASA 







> .... ... 
~ 
21 28 35 42 49 56 0~------~----~------~------~------+-------~----~------~ 14 0 7 14 21 26 3!5 42 49 56 
TIME (DAYS) TIHE (OAYSI 
Mean relative stimulation indices to heat killed ~ abortus-induced 
culture supernatant fluid. The vaccine and adjuvant preparations 
group of animals are shown in table 1. 
IL-2 production in 





-CONTIIDL I t - COHTliCl. ---•u 
sl --- 5 -a- 88.UA+OD.t. 
i 4 >< -H- illlAIAtODA...:P ~ 4 
i!i -\'- 8!1ASA+OD.t. +TOM a ... ... 
a3 
1-c 
~ 3 ... ... 
1- Iii rn 
!I;! IIJ > ... ... 
~2 ~ 2 
a: a: 
0 0 7 1~ 21 28 35 42 49 56 0 o 7 ~ ~ ~ ~ ~ ~ ~ 
TIME (DAYS) TIME (DAYS) 
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
Bovine brucellosis caused by Brucella abortus is an economically 
important disease associated with abortion and infertility. Despite 
numerous methods of eradication including vaccination, and test and 
slaughter, the disease has remained prevalent in many areas of the 
world. 
The use of !h abortus strain 19 ( Sl9) vaccine in cattle does 
provide protection from abortion but its use can cause cattle to 
become seropositive or even develop persistent infections with S19. 
Furthermore, S19, although attenuated for cattle is virulent for 
humans and thus constitutes a human health hazard. Some of the 
problems associated with Sl9 have been decreased but not eliminated by 
using a reduced vaccinal dose. The problems currently associated with 
Sl9 vaccine have generated interest in the development of a non-living 
(subunit) !h abortus vaccine. 
However, non-living (subunit) vaccines are often weakly 
immunogenic and require the use of adjuvants to enhance their 
immunogenic potential. By augmenting the efficacy of vaccination, an 
appropriate adjuvant could induce long-lasting immunity using a low 
dose of antigen and thus minimizing side effects of vaccination. 
Numerous investigators have tested various non-living (subunit) 
vaccines in experimental bovine brucellosis. Variable degrees of 
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success were seen. 
The studies in this dissertation were conducted to evaluate in 
cattle, the immunopotentiating effects of various adjuvants for use 
with non-living ~ abortus antigens through comparison of serum 
antibody and CMI responses induced by these experimental vaccines. 
Additionally, the CMI responses were assessed with regard to 
functional lymphocyte and mononuclear phagocyte activities from the 
peripheral blood of calves vaccinated with Sl9 or non-living (subunit) 
vaccines. 
Cattle were immunized with ~ abortus soluble antigen (BASA) or a 
soluble extract of gamma-irradiated ~ abortus (GBASA) in combination 
with various adjuvant preparations. GBASA had a reduced LPS content 
as compared to BASA. The humoral immune responses were measured using 
standard serologic tests and immunoassays. The CMI responses were 
evaluated using the lymphoproliferative assay and cutaneous DTH 
responses. Specific aspects of induced CMI responses investigated 
were macrophage activation (IL-l production), T-helper cell ( IL-2 
production), and suppressor cell activity. 
The findings reported in this work demonstrated a marked 
variability in the ability of different adjuvants to augment both 
humoral and CMI responses when administered with BASA and GBASA. A 
single administration of antigen was used to study the primary 
response in comparison to the single inoculation with Sl9 as a 
standard. Humoral and CMI responses were lowest when no adjuvant was 
included with the antigen. 
In experiment 1, FIA provided the greatest stimulus for antibody 
production, whereas in Experiments 2 and 3, the largest antibody 
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titers were evident in the Sl9 group. GBASA-adjuvanted vaccines 
produced lower antibody titers than BASA-adjuvanted vaccines. These 
may be due to the low LPS content in GBASA as compared to BASA. Cell-
mediated immune responses as determined by LP assay and DTH tests were 
most evident in Sl9, BASA + DDA and GBASA + DDA + TOM vaccinates, with 
the highest responses occurring in 519 vaccinates. 
The ability of an individual's lymphocytes to produce and respond 
to IL-2 may provide a quantitative measure of CMI responses to 
specific antigens. In the present study, Sl9 and DDA provided the 
greatest stimulus for IL-2 production, which in most instances 
corresponded with the LP responses. IL-l modulates many of the 
responses involved in the process of host defense against infection. 
Many agents exert their adjuvant effects by inducing the release of 
IL-l from macrophages. In the present study DDA provided the 
strongest stimulus for IL-l production. The stimulatory effect of DDA 
on macrophages may be particularly important because ~ abortus is an 
intracellular pathogen and macrophages may be important in host 
defense in bovine brucellosis. 
Inhibition of the LP response to several mitogens was described 
in experimental murine brucellosis. In the present study soluble 
suppressor factors were demonstrated in the culture fluids of ~ 
abortus antigen-stimulated PBMC from cattle immunized with BASA 
adjuvanted vaccines. Generally, soluble suppressor factor(s) was not 
detected in lymphocyte cultures from cattle immunized with GBASA-
adjuvanted vaccines. This could be due to the low content of LPS in 
GBASA as compared to BASA. LPS has been shown to down regulate 
lymphokine production and T-cell responses. 
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Development of an improved and effective non-living !!.:.. abortus 
vaccine would constitute major progress toward the goal of eradicating 
bovine brucellosis in the United States. However, successful 
application of adjuvants to subunit vaccines will depend on the 
understanding of the mechanisms of action of the adjuvant and the 
appropriate factors and segments of the immune system that must be 
stimulated. The studies reported herein demonstrated that DDA 
potentiates CMI responses to non-living, soluble !!.:.. abortus antigens 
and may be useful as an adjuvant for future vaccines, particularly 
subunit vaccines. 
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